nodes	percent_of_prediction	percent_of_DWPC	metapath
Sunitinib—kidney cancer—urinary bladder cancer	0.531	1	CtDrD
Sunitinib—ABCC4—Fluorouracil—urinary bladder cancer	0.0145	0.115	CbGbCtD
Sunitinib—ABCB1—Mitomycin—urinary bladder cancer	0.0114	0.0903	CbGbCtD
Sunitinib—ABCC2—Carboplatin—urinary bladder cancer	0.00856	0.0678	CbGbCtD
Sunitinib—ABCC4—Methotrexate—urinary bladder cancer	0.00799	0.0632	CbGbCtD
Sunitinib—ABCG2—Fluorouracil—urinary bladder cancer	0.00779	0.0617	CbGbCtD
Sunitinib—ABCG2—Carboplatin—urinary bladder cancer	0.00774	0.0613	CbGbCtD
Sunitinib—ABCC2—Cisplatin—urinary bladder cancer	0.00732	0.0579	CbGbCtD
Sunitinib—ABCC2—Etoposide—urinary bladder cancer	0.00719	0.0569	CbGbCtD
Sunitinib—ABCG2—Cisplatin—urinary bladder cancer	0.00662	0.0524	CbGbCtD
Sunitinib—ABCG2—Etoposide—urinary bladder cancer	0.0065	0.0515	CbGbCtD
Sunitinib—CYP3A4—Thiotepa—urinary bladder cancer	0.00518	0.041	CbGbCtD
Sunitinib—ABCC2—Doxorubicin—urinary bladder cancer	0.0049	0.0388	CbGbCtD
Sunitinib—ABCC2—Methotrexate—urinary bladder cancer	0.00475	0.0376	CbGbCtD
Sunitinib—ABCG2—Doxorubicin—urinary bladder cancer	0.00443	0.0351	CbGbCtD
Sunitinib—ABCG2—Methotrexate—urinary bladder cancer	0.0043	0.034	CbGbCtD
Sunitinib—CYP3A5—Etoposide—urinary bladder cancer	0.0036	0.0285	CbGbCtD
Sunitinib—ABCB1—Gemcitabine—urinary bladder cancer	0.00328	0.026	CbGbCtD
Sunitinib—ABCB1—Cisplatin—urinary bladder cancer	0.00239	0.0189	CbGbCtD
Sunitinib—ABCB1—Etoposide—urinary bladder cancer	0.00234	0.0186	CbGbCtD
Sunitinib—ABCB1—Doxorubicin—urinary bladder cancer	0.0016	0.0127	CbGbCtD
Sunitinib—ABCB1—Methotrexate—urinary bladder cancer	0.00155	0.0123	CbGbCtD
Sunitinib—CYP3A4—Etoposide—urinary bladder cancer	0.0014	0.0111	CbGbCtD
Sunitinib—CYP3A4—Doxorubicin—urinary bladder cancer	0.000958	0.00758	CbGbCtD
Sunitinib—STK24—Teniposide—Etoposide—urinary bladder cancer	0.000248	0.0836	CbGdCrCtD
Sunitinib—DYRK1A—Idarubicin—Valrubicin—urinary bladder cancer	0.000173	0.0584	CbGdCrCtD
Sunitinib—DYRK1A—Daunorubicin—Valrubicin—urinary bladder cancer	0.000173	0.0584	CbGdCrCtD
Sunitinib—DYRK1A—Epirubicin—Valrubicin—urinary bladder cancer	0.000173	0.0584	CbGdCrCtD
Sunitinib—DYRK1A—Doxorubicin—Valrubicin—urinary bladder cancer	0.000173	0.0584	CbGdCrCtD
Sunitinib—PRPF4—Idarubicin—Valrubicin—urinary bladder cancer	0.000149	0.0504	CbGdCrCtD
Sunitinib—PRPF4—Daunorubicin—Valrubicin—urinary bladder cancer	0.000149	0.0504	CbGdCrCtD
Sunitinib—MAP3K12—female reproductive system—urinary bladder cancer	0.000137	0.00128	CbGeAlD
Sunitinib—FLT3—female reproductive system—urinary bladder cancer	0.000137	0.00128	CbGeAlD
Sunitinib—RPS6KA5—lymph node—urinary bladder cancer	0.000136	0.00128	CbGeAlD
Sunitinib—STK3—vagina—urinary bladder cancer	0.000136	0.00128	CbGeAlD
Sunitinib—RPS6KB1—urethra—urinary bladder cancer	0.000135	0.00127	CbGeAlD
Sunitinib—FGFR2—smooth muscle tissue—urinary bladder cancer	0.000135	0.00127	CbGeAlD
Sunitinib—RPS6KA3—female reproductive system—urinary bladder cancer	0.000135	0.00127	CbGeAlD
Sunitinib—FGR—urethra—urinary bladder cancer	0.000134	0.00126	CbGeAlD
Sunitinib—JAK2—smooth muscle tissue—urinary bladder cancer	0.000134	0.00126	CbGeAlD
Sunitinib—MAP2K1—female reproductive system—urinary bladder cancer	0.000134	0.00126	CbGeAlD
Sunitinib—AXL—urethra—urinary bladder cancer	0.000134	0.00126	CbGeAlD
Sunitinib—FYN—smooth muscle tissue—urinary bladder cancer	0.000132	0.00125	CbGeAlD
Sunitinib—KIT—prostate gland—urinary bladder cancer	0.000132	0.00125	CbGeAlD
Sunitinib—CSNK1A1—female reproductive system—urinary bladder cancer	0.000132	0.00124	CbGeAlD
Sunitinib—CLK1—female reproductive system—urinary bladder cancer	0.000131	0.00123	CbGeAlD
Sunitinib—CLK4—lymph node—urinary bladder cancer	0.000131	0.00123	CbGeAlD
Sunitinib—FGFR2—renal system—urinary bladder cancer	0.00013	0.00122	CbGeAlD
Sunitinib—FLT1—epithelium—urinary bladder cancer	0.00013	0.00122	CbGeAlD
Sunitinib—ITK—lymph node—urinary bladder cancer	0.00013	0.00122	CbGeAlD
Sunitinib—SBK1—lymph node—urinary bladder cancer	0.00013	0.00122	CbGeAlD
Sunitinib—MAP4K5—smooth muscle tissue—urinary bladder cancer	0.000129	0.00122	CbGeAlD
Sunitinib—PDGFRB—prostate gland—urinary bladder cancer	0.000129	0.00122	CbGeAlD
Sunitinib—JAK2—renal system—urinary bladder cancer	0.000129	0.00122	CbGeAlD
Sunitinib—BMP2K—female reproductive system—urinary bladder cancer	0.000129	0.00121	CbGeAlD
Sunitinib—CAMK2G—female reproductive system—urinary bladder cancer	0.000129	0.00121	CbGeAlD
Sunitinib—SLK—urethra—urinary bladder cancer	0.000129	0.00121	CbGeAlD
Sunitinib—BLK—lymph node—urinary bladder cancer	0.000128	0.00121	CbGeAlD
Sunitinib—MERTK—vagina—urinary bladder cancer	0.000128	0.0012	CbGeAlD
Sunitinib—LRRK2—female reproductive system—urinary bladder cancer	0.000128	0.0012	CbGeAlD
Sunitinib—FYN—renal system—urinary bladder cancer	0.000127	0.0012	CbGeAlD
Sunitinib—JAK2—urethra—urinary bladder cancer	0.000127	0.00119	CbGeAlD
Sunitinib—PHKG1—lymph node—urinary bladder cancer	0.000127	0.00119	CbGeAlD
Sunitinib—DAPK1—lymph node—urinary bladder cancer	0.000127	0.00119	CbGeAlD
Sunitinib—KDR—seminal vesicle—urinary bladder cancer	0.000126	0.00119	CbGeAlD
Sunitinib—MAP2K5—seminal vesicle—urinary bladder cancer	0.000126	0.00119	CbGeAlD
Sunitinib—PRKAA1—female reproductive system—urinary bladder cancer	0.000126	0.00118	CbGeAlD
Sunitinib—MAP4K4—vagina—urinary bladder cancer	0.000125	0.00118	CbGeAlD
Sunitinib—FYN—urethra—urinary bladder cancer	0.000125	0.00118	CbGeAlD
Sunitinib—FLT1—smooth muscle tissue—urinary bladder cancer	0.000125	0.00118	CbGeAlD
Sunitinib—NUAK2—vagina—urinary bladder cancer	0.000124	0.00117	CbGeAlD
Sunitinib—PTK2B—female reproductive system—urinary bladder cancer	0.000124	0.00117	CbGeAlD
Sunitinib—FLT4—female reproductive system—urinary bladder cancer	0.000124	0.00117	CbGeAlD
Sunitinib—MAP3K12—vagina—urinary bladder cancer	0.000123	0.00116	CbGeAlD
Sunitinib—CSF1R—seminal vesicle—urinary bladder cancer	0.000123	0.00116	CbGeAlD
Sunitinib—STK11—lymph node—urinary bladder cancer	0.000123	0.00115	CbGeAlD
Sunitinib—BRD4—lymph node—urinary bladder cancer	0.000123	0.00115	CbGeAlD
Sunitinib—CSNK1E—female reproductive system—urinary bladder cancer	0.000122	0.00115	CbGeAlD
Sunitinib—MAP3K3—urethra—urinary bladder cancer	0.000122	0.00115	CbGeAlD
Sunitinib—MAP4K5—urethra—urinary bladder cancer	0.000122	0.00115	CbGeAlD
Sunitinib—RPS6KA3—vagina—urinary bladder cancer	0.000122	0.00115	CbGeAlD
Sunitinib—RPS6KA1—lymph node—urinary bladder cancer	0.000121	0.00114	CbGeAlD
Sunitinib—RIOK1—lymph node—urinary bladder cancer	0.000121	0.00114	CbGeAlD
Sunitinib—FLT1—renal system—urinary bladder cancer	0.00012	0.00113	CbGeAlD
Sunitinib—YES1—smooth muscle tissue—urinary bladder cancer	0.000119	0.00112	CbGeAlD
Sunitinib—CSNK1A1—vagina—urinary bladder cancer	0.000119	0.00112	CbGeAlD
Sunitinib—TNIK—lymph node—urinary bladder cancer	0.000119	0.00112	CbGeAlD
Sunitinib—MARK2—lymph node—urinary bladder cancer	0.000119	0.00112	CbGeAlD
Sunitinib—CLK1—vagina—urinary bladder cancer	0.000119	0.00112	CbGeAlD
Sunitinib—PLK4—Doxorubicin—Valrubicin—urinary bladder cancer	0.000118	0.0399	CbGdCrCtD
Sunitinib—PLK4—Epirubicin—Valrubicin—urinary bladder cancer	0.000118	0.0399	CbGdCrCtD
Sunitinib—PLK4—Idarubicin—Valrubicin—urinary bladder cancer	0.000118	0.0399	CbGdCrCtD
Sunitinib—FLT1—urethra—urinary bladder cancer	0.000118	0.00111	CbGeAlD
Sunitinib—SGK3—lymph node—urinary bladder cancer	0.000118	0.00111	CbGeAlD
Sunitinib—MAP2K2—female reproductive system—urinary bladder cancer	0.000118	0.00111	CbGeAlD
Sunitinib—ULK3—female reproductive system—urinary bladder cancer	0.000118	0.00111	CbGeAlD
Sunitinib—PDGFRA—smooth muscle tissue—urinary bladder cancer	0.000117	0.0011	CbGeAlD
Sunitinib—MAP3K2—female reproductive system—urinary bladder cancer	0.000117	0.0011	CbGeAlD
Sunitinib—EPHB6—urethra—urinary bladder cancer	0.000117	0.0011	CbGeAlD
Sunitinib—ICK—lymph node—urinary bladder cancer	0.000117	0.0011	CbGeAlD
Sunitinib—CAMK2G—vagina—urinary bladder cancer	0.000116	0.0011	CbGeAlD
Sunitinib—BMP2K—vagina—urinary bladder cancer	0.000116	0.0011	CbGeAlD
Sunitinib—LRRK2—vagina—urinary bladder cancer	0.000115	0.00109	CbGeAlD
Sunitinib—YES1—renal system—urinary bladder cancer	0.000115	0.00108	CbGeAlD
Sunitinib—TBK1—female reproductive system—urinary bladder cancer	0.000115	0.00108	CbGeAlD
Sunitinib—STK10—renal system—urinary bladder cancer	0.000114	0.00107	CbGeAlD
Sunitinib—TYK2—female reproductive system—urinary bladder cancer	0.000114	0.00107	CbGeAlD
Sunitinib—TAOK3—renal system—urinary bladder cancer	0.000114	0.00107	CbGeAlD
Sunitinib—YES1—urethra—urinary bladder cancer	0.000113	0.00106	CbGeAlD
Sunitinib—CHEK2—lymph node—urinary bladder cancer	0.000113	0.00106	CbGeAlD
Sunitinib—NUAK1—lymph node—urinary bladder cancer	0.000113	0.00106	CbGeAlD
Sunitinib—PDGFRA—renal system—urinary bladder cancer	0.000113	0.00106	CbGeAlD
Sunitinib—PTK2B—vagina—urinary bladder cancer	0.000112	0.00106	CbGeAlD
Sunitinib—IRAK1—female reproductive system—urinary bladder cancer	0.000112	0.00106	CbGeAlD
Sunitinib—CAMK2G—Azacitidine—Gemcitabine—urinary bladder cancer	0.000112	0.0378	CbGdCrCtD
Sunitinib—OXSR1—lymph node—urinary bladder cancer	0.000112	0.00105	CbGeAlD
Sunitinib—INSR—lymph node—urinary bladder cancer	0.000112	0.00105	CbGeAlD
Sunitinib—SNRK—lymph node—urinary bladder cancer	0.000112	0.00105	CbGeAlD
Sunitinib—KIT—seminal vesicle—urinary bladder cancer	0.000112	0.00105	CbGeAlD
Sunitinib—TAOK3—urethra—urinary bladder cancer	0.000112	0.00105	CbGeAlD
Sunitinib—CSNK1E—vagina—urinary bladder cancer	0.000111	0.00104	CbGeAlD
Sunitinib—FGFR1—vagina—urinary bladder cancer	0.000111	0.00104	CbGeAlD
Sunitinib—STK38—lymph node—urinary bladder cancer	0.00011	0.00104	CbGeAlD
Sunitinib—RPS6KA2—lymph node—urinary bladder cancer	0.00011	0.00104	CbGeAlD
Sunitinib—RPS6KB1—female reproductive system—urinary bladder cancer	0.00011	0.00104	CbGeAlD
Sunitinib—KDR—epithelium—urinary bladder cancer	0.00011	0.00103	CbGeAlD
Sunitinib—FGR—female reproductive system—urinary bladder cancer	0.000109	0.00103	CbGeAlD
Sunitinib—AURKC—lymph node—urinary bladder cancer	0.000109	0.00103	CbGeAlD
Sunitinib—PDGFRB—seminal vesicle—urinary bladder cancer	0.000109	0.00103	CbGeAlD
Sunitinib—AXL—female reproductive system—urinary bladder cancer	0.000109	0.00103	CbGeAlD
Sunitinib—IRAK4—vagina—urinary bladder cancer	0.000109	0.00103	CbGeAlD
Sunitinib—CSNK1G2—lymph node—urinary bladder cancer	0.000109	0.00102	CbGeAlD
Sunitinib—PKN1—lymph node—urinary bladder cancer	0.000109	0.00102	CbGeAlD
Sunitinib—PRPF4—lymph node—urinary bladder cancer	0.000107	0.00101	CbGeAlD
Sunitinib—ULK3—vagina—urinary bladder cancer	0.000107	0.001	CbGeAlD
Sunitinib—KDR—smooth muscle tissue—urinary bladder cancer	0.000106	0.000995	CbGeAlD
Sunitinib—PRPF4B—lymph node—urinary bladder cancer	0.000105	0.000992	CbGeAlD
Sunitinib—MAP3K7—vagina—urinary bladder cancer	0.000105	0.000986	CbGeAlD
Sunitinib—CHEK2—Doxorubicin—Valrubicin—urinary bladder cancer	0.000104	0.0351	CbGdCrCtD
Sunitinib—CHEK2—Epirubicin—Valrubicin—urinary bladder cancer	0.000104	0.0351	CbGdCrCtD
Sunitinib—FGFR2—female reproductive system—urinary bladder cancer	0.000104	0.000979	CbGeAlD
Sunitinib—STK39—lymph node—urinary bladder cancer	0.000104	0.000978	CbGeAlD
Sunitinib—TBK1—vagina—urinary bladder cancer	0.000104	0.000975	CbGeAlD
Sunitinib—JAK2—female reproductive system—urinary bladder cancer	0.000103	0.000974	CbGeAlD
Sunitinib—CSF1R—smooth muscle tissue—urinary bladder cancer	0.000103	0.000971	CbGeAlD
Sunitinib—ABCC4—prostate gland—urinary bladder cancer	0.000103	0.000968	CbGeAlD
Sunitinib—TYK2—vagina—urinary bladder cancer	0.000103	0.000968	CbGeAlD
Sunitinib—CSNK2A1—lymph node—urinary bladder cancer	0.000103	0.000965	CbGeAlD
Sunitinib—FYN—female reproductive system—urinary bladder cancer	0.000102	0.00096	CbGeAlD
Sunitinib—KDR—renal system—urinary bladder cancer	0.000102	0.000958	CbGeAlD
Sunitinib—MYLK—lymph node—urinary bladder cancer	0.000101	0.000953	CbGeAlD
Sunitinib—PLK4—lymph node—urinary bladder cancer	0.0001	0.000941	CbGeAlD
Sunitinib—MAP2K5—urethra—urinary bladder cancer	0.0001	0.000941	CbGeAlD
Sunitinib—KDR—urethra—urinary bladder cancer	0.0001	0.000941	CbGeAlD
Sunitinib—MAP4K5—female reproductive system—urinary bladder cancer	9.97e-05	0.000939	CbGeAlD
Sunitinib—MAP3K3—female reproductive system—urinary bladder cancer	9.97e-05	0.000939	CbGeAlD
Sunitinib—RPS6KB1—vagina—urinary bladder cancer	9.96e-05	0.000938	CbGeAlD
Sunitinib—ABCC2—prostate gland—urinary bladder cancer	9.96e-05	0.000937	CbGeAlD
Sunitinib—STK4—lymph node—urinary bladder cancer	9.94e-05	0.000935	CbGeAlD
Sunitinib—FGR—vagina—urinary bladder cancer	9.9e-05	0.000932	CbGeAlD
Sunitinib—AXL—vagina—urinary bladder cancer	9.86e-05	0.000928	CbGeAlD
Sunitinib—PHKG2—lymph node—urinary bladder cancer	9.76e-05	0.000919	CbGeAlD
Sunitinib—CSF1R—urethra—urinary bladder cancer	9.76e-05	0.000918	CbGeAlD
Sunitinib—KIT—epithelium—urinary bladder cancer	9.72e-05	0.000915	CbGeAlD
Sunitinib—STK24—lymph node—urinary bladder cancer	9.71e-05	0.000914	CbGeAlD
Sunitinib—FLT1—female reproductive system—urinary bladder cancer	9.64e-05	0.000907	CbGeAlD
Sunitinib—DAPK2—lymph node—urinary bladder cancer	9.6e-05	0.000903	CbGeAlD
Sunitinib—PDGFRB—epithelium—urinary bladder cancer	9.5e-05	0.000894	CbGeAlD
Sunitinib—SLK—vagina—urinary bladder cancer	9.49e-05	0.000893	CbGeAlD
Sunitinib—STK16—lymph node—urinary bladder cancer	9.44e-05	0.000889	CbGeAlD
Sunitinib—HIPK3—lymph node—urinary bladder cancer	9.39e-05	0.000884	CbGeAlD
Sunitinib—HIPK2—lymph node—urinary bladder cancer	9.39e-05	0.000884	CbGeAlD
Sunitinib—ALK—lymph node—urinary bladder cancer	9.39e-05	0.000884	CbGeAlD
Sunitinib—KIT—smooth muscle tissue—urinary bladder cancer	9.37e-05	0.000882	CbGeAlD
Sunitinib—JAK2—vagina—urinary bladder cancer	9.36e-05	0.000881	CbGeAlD
Sunitinib—RIOK2—lymph node—urinary bladder cancer	9.3e-05	0.000875	CbGeAlD
Sunitinib—TNK1—lymph node—urinary bladder cancer	9.3e-05	0.000875	CbGeAlD
Sunitinib—FYN—vagina—urinary bladder cancer	9.23e-05	0.000869	CbGeAlD
Sunitinib—YES1—female reproductive system—urinary bladder cancer	9.21e-05	0.000867	CbGeAlD
Sunitinib—MAP4K1—lymph node—urinary bladder cancer	9.2e-05	0.000866	CbGeAlD
Sunitinib—PDGFRB—smooth muscle tissue—urinary bladder cancer	9.15e-05	0.000861	CbGeAlD
Sunitinib—STK10—female reproductive system—urinary bladder cancer	9.13e-05	0.000859	CbGeAlD
Sunitinib—TAOK3—female reproductive system—urinary bladder cancer	9.09e-05	0.000856	CbGeAlD
Sunitinib—PDGFRA—female reproductive system—urinary bladder cancer	9.04e-05	0.00085	CbGeAlD
Sunitinib—DAPK3—lymph node—urinary bladder cancer	9.03e-05	0.000849	CbGeAlD
Sunitinib—MAP4K5—vagina—urinary bladder cancer	9.02e-05	0.000849	CbGeAlD
Sunitinib—MAP3K3—vagina—urinary bladder cancer	9.02e-05	0.000849	CbGeAlD
Sunitinib—KIT—renal system—urinary bladder cancer	9.02e-05	0.000849	CbGeAlD
Sunitinib—CLK2—lymph node—urinary bladder cancer	8.94e-05	0.000841	CbGeAlD
Sunitinib—MAP4K2—lymph node—urinary bladder cancer	8.9e-05	0.000837	CbGeAlD
Sunitinib—KIT—urethra—urinary bladder cancer	8.86e-05	0.000834	CbGeAlD
Sunitinib—PDGFRB—renal system—urinary bladder cancer	8.81e-05	0.000829	CbGeAlD
Sunitinib—STK3—lymph node—urinary bladder cancer	8.78e-05	0.000826	CbGeAlD
Sunitinib—FLT1—vagina—urinary bladder cancer	8.72e-05	0.000821	CbGeAlD
Sunitinib—PDGFRB—urethra—urinary bladder cancer	8.65e-05	0.000814	CbGeAlD
Sunitinib—EPHB6—vagina—urinary bladder cancer	8.62e-05	0.000811	CbGeAlD
Sunitinib—DYRK1A—lymph node—urinary bladder cancer	8.45e-05	0.000795	CbGeAlD
Sunitinib—YES1—vagina—urinary bladder cancer	8.33e-05	0.000784	CbGeAlD
Sunitinib—STK10—vagina—urinary bladder cancer	8.26e-05	0.000777	CbGeAlD
Sunitinib—MERTK—lymph node—urinary bladder cancer	8.25e-05	0.000777	CbGeAlD
Sunitinib—TAOK3—vagina—urinary bladder cancer	8.22e-05	0.000774	CbGeAlD
Sunitinib—PDGFRA—vagina—urinary bladder cancer	8.17e-05	0.000769	CbGeAlD
Sunitinib—KCNH2—prostate gland—urinary bladder cancer	8.17e-05	0.000768	CbGeAlD
Sunitinib—KDR—female reproductive system—urinary bladder cancer	8.15e-05	0.000767	CbGeAlD
Sunitinib—MAP2K5—female reproductive system—urinary bladder cancer	8.15e-05	0.000767	CbGeAlD
Sunitinib—MAP4K4—lymph node—urinary bladder cancer	8.1e-05	0.000762	CbGeAlD
Sunitinib—NUAK2—lymph node—urinary bladder cancer	8.04e-05	0.000757	CbGeAlD
Sunitinib—MAP3K12—lymph node—urinary bladder cancer	7.99e-05	0.000752	CbGeAlD
Sunitinib—FLT3—lymph node—urinary bladder cancer	7.99e-05	0.000752	CbGeAlD
Sunitinib—CSF1R—female reproductive system—urinary bladder cancer	7.96e-05	0.000749	CbGeAlD
Sunitinib—PLK4—Teniposide—Etoposide—urinary bladder cancer	7.89e-05	0.0266	CbGdCrCtD
Sunitinib—RPS6KA3—lymph node—urinary bladder cancer	7.88e-05	0.000741	CbGeAlD
Sunitinib—MAP2K1—lymph node—urinary bladder cancer	7.83e-05	0.000736	CbGeAlD
Sunitinib—CSNK1A1—lymph node—urinary bladder cancer	7.72e-05	0.000727	CbGeAlD
Sunitinib—CLK1—lymph node—urinary bladder cancer	7.67e-05	0.000722	CbGeAlD
Sunitinib—BMP2K—lymph node—urinary bladder cancer	7.53e-05	0.000709	CbGeAlD
Sunitinib—CAMK2G—lymph node—urinary bladder cancer	7.53e-05	0.000709	CbGeAlD
Sunitinib—LRRK2—lymph node—urinary bladder cancer	7.47e-05	0.000703	CbGeAlD
Sunitinib—KDR—vagina—urinary bladder cancer	7.37e-05	0.000694	CbGeAlD
Sunitinib—MAP2K5—vagina—urinary bladder cancer	7.37e-05	0.000694	CbGeAlD
Sunitinib—PRKAA1—lymph node—urinary bladder cancer	7.36e-05	0.000692	CbGeAlD
Sunitinib—PTK2B—lymph node—urinary bladder cancer	7.28e-05	0.000685	CbGeAlD
Sunitinib—ABCG2—prostate gland—urinary bladder cancer	7.26e-05	0.000684	CbGeAlD
Sunitinib—FLT4—lymph node—urinary bladder cancer	7.26e-05	0.000683	CbGeAlD
Sunitinib—KIT—female reproductive system—urinary bladder cancer	7.22e-05	0.00068	CbGeAlD
Sunitinib—CSF1R—vagina—urinary bladder cancer	7.19e-05	0.000677	CbGeAlD
Sunitinib—CSNK1E—lymph node—urinary bladder cancer	7.16e-05	0.000674	CbGeAlD
Sunitinib—FGFR1—lymph node—urinary bladder cancer	7.16e-05	0.000674	CbGeAlD
Sunitinib—PDGFRB—female reproductive system—urinary bladder cancer	7.06e-05	0.000664	CbGeAlD
Sunitinib—IRAK4—lymph node—urinary bladder cancer	7.05e-05	0.000663	CbGeAlD
Sunitinib—ABCC4—renal system—urinary bladder cancer	7.01e-05	0.00066	CbGeAlD
Sunitinib—CHEK2—Teniposide—Etoposide—urinary bladder cancer	6.96e-05	0.0234	CbGdCrCtD
Sunitinib—CHEK2—Podofilox—Etoposide—urinary bladder cancer	6.96e-05	0.0234	CbGdCrCtD
Sunitinib—KCNH2—seminal vesicle—urinary bladder cancer	6.91e-05	0.00065	CbGeAlD
Sunitinib—MAP2K2—lymph node—urinary bladder cancer	6.89e-05	0.000648	CbGeAlD
Sunitinib—ULK3—lymph node—urinary bladder cancer	6.89e-05	0.000648	CbGeAlD
Sunitinib—MAP3K2—lymph node—urinary bladder cancer	6.84e-05	0.000644	CbGeAlD
Sunitinib—ABCC2—renal system—urinary bladder cancer	6.79e-05	0.000639	CbGeAlD
Sunitinib—MAP3K7—lymph node—urinary bladder cancer	6.78e-05	0.000638	CbGeAlD
Sunitinib—CYP3A5—prostate gland—urinary bladder cancer	6.74e-05	0.000635	CbGeAlD
Sunitinib—TBK1—lymph node—urinary bladder cancer	6.7e-05	0.00063	CbGeAlD
Sunitinib—TYK2—lymph node—urinary bladder cancer	6.65e-05	0.000626	CbGeAlD
Sunitinib—IRAK1—lymph node—urinary bladder cancer	6.57e-05	0.000618	CbGeAlD
Sunitinib—KIT—vagina—urinary bladder cancer	6.53e-05	0.000615	CbGeAlD
Sunitinib—RPS6KB1—lymph node—urinary bladder cancer	6.44e-05	0.000606	CbGeAlD
Sunitinib—FGR—lymph node—urinary bladder cancer	6.41e-05	0.000603	CbGeAlD
Sunitinib—RET—lymph node—urinary bladder cancer	6.41e-05	0.000603	CbGeAlD
Sunitinib—PDGFRB—vagina—urinary bladder cancer	6.38e-05	0.0006	CbGeAlD
Sunitinib—AXL—lymph node—urinary bladder cancer	6.38e-05	0.0006	CbGeAlD
Sunitinib—ABCG2—seminal vesicle—urinary bladder cancer	6.14e-05	0.000578	CbGeAlD
Sunitinib—SLK—lymph node—urinary bladder cancer	6.14e-05	0.000578	CbGeAlD
Sunitinib—JAK2—lymph node—urinary bladder cancer	6.05e-05	0.00057	CbGeAlD
Sunitinib—DYRK1A—Doxorubicin—Epirubicin—urinary bladder cancer	6.03e-05	0.0203	CbGdCrCtD
Sunitinib—DYRK1A—Daunorubicin—Epirubicin—urinary bladder cancer	6.03e-05	0.0203	CbGdCrCtD
Sunitinib—DYRK1A—Idarubicin—Epirubicin—urinary bladder cancer	6.03e-05	0.0203	CbGdCrCtD
Sunitinib—FYN—lymph node—urinary bladder cancer	5.97e-05	0.000562	CbGeAlD
Sunitinib—MAP4K5—lymph node—urinary bladder cancer	5.83e-05	0.000549	CbGeAlD
Sunitinib—MAP3K3—lymph node—urinary bladder cancer	5.83e-05	0.000549	CbGeAlD
Sunitinib—RPS6KA1—Azacitidine—Gemcitabine—urinary bladder cancer	5.74e-05	0.0194	CbGdCrCtD
Sunitinib—FLT1—lymph node—urinary bladder cancer	5.64e-05	0.000531	CbGeAlD
Sunitinib—ABCC4—female reproductive system—urinary bladder cancer	5.62e-05	0.000529	CbGeAlD
Sunitinib—EPHB6—lymph node—urinary bladder cancer	5.58e-05	0.000525	CbGeAlD
Sunitinib—DYRK1A—Epirubicin—Doxorubicin—urinary bladder cancer	5.58e-05	0.0188	CbGdCrCtD
Sunitinib—DYRK1A—Daunorubicin—Doxorubicin—urinary bladder cancer	5.58e-05	0.0188	CbGdCrCtD
Sunitinib—DYRK1A—Idarubicin—Doxorubicin—urinary bladder cancer	5.58e-05	0.0188	CbGdCrCtD
Sunitinib—KCNH2—renal system—urinary bladder cancer	5.57e-05	0.000524	CbGeAlD
Sunitinib—KCNH2—urethra—urinary bladder cancer	5.47e-05	0.000515	CbGeAlD
Sunitinib—ABCC2—female reproductive system—urinary bladder cancer	5.44e-05	0.000512	CbGeAlD
Sunitinib—YES1—lymph node—urinary bladder cancer	5.39e-05	0.000507	CbGeAlD
Sunitinib—STK10—lymph node—urinary bladder cancer	5.34e-05	0.000502	CbGeAlD
Sunitinib—TAOK3—lymph node—urinary bladder cancer	5.32e-05	0.000501	CbGeAlD
Sunitinib—PDGFRA—lymph node—urinary bladder cancer	5.29e-05	0.000497	CbGeAlD
Sunitinib—PRPF4—Daunorubicin—Epirubicin—urinary bladder cancer	5.2e-05	0.0175	CbGdCrCtD
Sunitinib—PRPF4—Idarubicin—Epirubicin—urinary bladder cancer	5.2e-05	0.0175	CbGdCrCtD
Sunitinib—ABCG2—urethra—urinary bladder cancer	4.86e-05	0.000458	CbGeAlD
Sunitinib—PRPF4—Daunorubicin—Doxorubicin—urinary bladder cancer	4.81e-05	0.0162	CbGdCrCtD
Sunitinib—PRPF4—Idarubicin—Doxorubicin—urinary bladder cancer	4.81e-05	0.0162	CbGdCrCtD
Sunitinib—KDR—lymph node—urinary bladder cancer	4.77e-05	0.000449	CbGeAlD
Sunitinib—MAP2K5—lymph node—urinary bladder cancer	4.77e-05	0.000449	CbGeAlD
Sunitinib—CSF1R—lymph node—urinary bladder cancer	4.65e-05	0.000438	CbGeAlD
Sunitinib—CYP3A5—renal system—urinary bladder cancer	4.6e-05	0.000433	CbGeAlD
Sunitinib—KCNH2—female reproductive system—urinary bladder cancer	4.46e-05	0.000419	CbGeAlD
Sunitinib—Decreased appetite—Etoposide—urinary bladder cancer	4.36e-05	0.00043	CcSEcCtD
Sunitinib—Pancytopenia—Doxorubicin—urinary bladder cancer	4.34e-05	0.000429	CcSEcCtD
Sunitinib—Renal failure—Epirubicin—urinary bladder cancer	4.33e-05	0.000428	CcSEcCtD
Sunitinib—Gastrointestinal disorder—Etoposide—urinary bladder cancer	4.33e-05	0.000427	CcSEcCtD
Sunitinib—Body temperature increased—Cisplatin—urinary bladder cancer	4.32e-05	0.000427	CcSEcCtD
Sunitinib—Fatigue—Etoposide—urinary bladder cancer	4.32e-05	0.000427	CcSEcCtD
Sunitinib—Neuropathy peripheral—Epirubicin—urinary bladder cancer	4.32e-05	0.000426	CcSEcCtD
Sunitinib—Stomatitis—Epirubicin—urinary bladder cancer	4.29e-05	0.000424	CcSEcCtD
Sunitinib—Constipation—Etoposide—urinary bladder cancer	4.29e-05	0.000423	CcSEcCtD
Sunitinib—Pain—Etoposide—urinary bladder cancer	4.29e-05	0.000423	CcSEcCtD
Sunitinib—Urinary tract infection—Epirubicin—urinary bladder cancer	4.28e-05	0.000423	CcSEcCtD
Sunitinib—Neutropenia—Doxorubicin—urinary bladder cancer	4.27e-05	0.000422	CcSEcCtD
Sunitinib—Hypersensitivity—Fluorouracil—urinary bladder cancer	4.25e-05	0.00042	CcSEcCtD
Sunitinib—Upper respiratory tract infection—Doxorubicin—urinary bladder cancer	4.25e-05	0.00042	CcSEcCtD
Sunitinib—Haemoglobin—Methotrexate—urinary bladder cancer	4.25e-05	0.000419	CcSEcCtD
Sunitinib—KIT—lymph node—urinary bladder cancer	4.23e-05	0.000398	CbGeAlD
Sunitinib—Haemorrhage—Methotrexate—urinary bladder cancer	4.23e-05	0.000417	CcSEcCtD
Sunitinib—Hepatitis—Methotrexate—urinary bladder cancer	4.23e-05	0.000417	CcSEcCtD
Sunitinib—Asthenia—Gemcitabine—urinary bladder cancer	4.21e-05	0.000416	CcSEcCtD
Sunitinib—Urinary tract disorder—Methotrexate—urinary bladder cancer	4.17e-05	0.000412	CcSEcCtD
Sunitinib—Hepatobiliary disease—Epirubicin—urinary bladder cancer	4.17e-05	0.000411	CcSEcCtD
Sunitinib—Epistaxis—Epirubicin—urinary bladder cancer	4.16e-05	0.00041	CcSEcCtD
Sunitinib—Pruritus—Gemcitabine—urinary bladder cancer	4.15e-05	0.00041	CcSEcCtD
Sunitinib—Nausea—Thiotepa—urinary bladder cancer	4.14e-05	0.000409	CcSEcCtD
Sunitinib—Urethral disorder—Methotrexate—urinary bladder cancer	4.14e-05	0.000409	CcSEcCtD
Sunitinib—Weight decreased—Doxorubicin—urinary bladder cancer	4.14e-05	0.000408	CcSEcCtD
Sunitinib—PDGFRB—lymph node—urinary bladder cancer	4.13e-05	0.000388	CbGeAlD
Sunitinib—Hyperglycaemia—Doxorubicin—urinary bladder cancer	4.12e-05	0.000407	CcSEcCtD
Sunitinib—PLK4—Idarubicin—Epirubicin—urinary bladder cancer	4.12e-05	0.0139	CbGdCrCtD
Sunitinib—PLK4—Doxorubicin—Epirubicin—urinary bladder cancer	4.12e-05	0.0139	CbGdCrCtD
Sunitinib—Pneumonia—Doxorubicin—urinary bladder cancer	4.1e-05	0.000405	CcSEcCtD
Sunitinib—Gastrointestinal pain—Etoposide—urinary bladder cancer	4.1e-05	0.000405	CcSEcCtD
Sunitinib—Pruritus—Fluorouracil—urinary bladder cancer	4.08e-05	0.000403	CcSEcCtD
Sunitinib—Infestation NOS—Doxorubicin—urinary bladder cancer	4.08e-05	0.000403	CcSEcCtD
Sunitinib—Infestation—Doxorubicin—urinary bladder cancer	4.08e-05	0.000403	CcSEcCtD
Sunitinib—Stevens-Johnson syndrome—Doxorubicin—urinary bladder cancer	4.04e-05	0.000399	CcSEcCtD
Sunitinib—KCNH2—vagina—urinary bladder cancer	4.03e-05	0.000379	CbGeAlD
Sunitinib—Hypersensitivity—Cisplatin—urinary bladder cancer	4.03e-05	0.000398	CcSEcCtD
Sunitinib—Bradycardia—Epirubicin—urinary bladder cancer	4.03e-05	0.000398	CcSEcCtD
Sunitinib—Diarrhoea—Gemcitabine—urinary bladder cancer	4.02e-05	0.000397	CcSEcCtD
Sunitinib—Renal failure—Doxorubicin—urinary bladder cancer	4.01e-05	0.000396	CcSEcCtD
Sunitinib—Erythema multiforme—Methotrexate—urinary bladder cancer	4e-05	0.000395	CcSEcCtD
Sunitinib—Neuropathy peripheral—Doxorubicin—urinary bladder cancer	4e-05	0.000395	CcSEcCtD
Sunitinib—Haemoglobin—Epirubicin—urinary bladder cancer	3.97e-05	0.000393	CcSEcCtD
Sunitinib—Stomatitis—Doxorubicin—urinary bladder cancer	3.97e-05	0.000392	CcSEcCtD
Sunitinib—Abdominal pain—Etoposide—urinary bladder cancer	3.96e-05	0.000391	CcSEcCtD
Sunitinib—Body temperature increased—Etoposide—urinary bladder cancer	3.96e-05	0.000391	CcSEcCtD
Sunitinib—Urinary tract infection—Doxorubicin—urinary bladder cancer	3.96e-05	0.000391	CcSEcCtD
Sunitinib—Haemorrhage—Epirubicin—urinary bladder cancer	3.95e-05	0.000391	CcSEcCtD
Sunitinib—Hepatitis—Epirubicin—urinary bladder cancer	3.95e-05	0.000391	CcSEcCtD
Sunitinib—Eye disorder—Methotrexate—urinary bladder cancer	3.95e-05	0.00039	CcSEcCtD
Sunitinib—Diarrhoea—Fluorouracil—urinary bladder cancer	3.95e-05	0.00039	CcSEcCtD
Sunitinib—Hypoaesthesia—Epirubicin—urinary bladder cancer	3.93e-05	0.000389	CcSEcCtD
Sunitinib—Asthenia—Cisplatin—urinary bladder cancer	3.93e-05	0.000388	CcSEcCtD
Sunitinib—Cardiac disorder—Methotrexate—urinary bladder cancer	3.92e-05	0.000387	CcSEcCtD
Sunitinib—Urinary tract disorder—Epirubicin—urinary bladder cancer	3.91e-05	0.000386	CcSEcCtD
Sunitinib—Oedema peripheral—Epirubicin—urinary bladder cancer	3.9e-05	0.000385	CcSEcCtD
Sunitinib—Connective tissue disorder—Epirubicin—urinary bladder cancer	3.89e-05	0.000384	CcSEcCtD
Sunitinib—Urethral disorder—Epirubicin—urinary bladder cancer	3.88e-05	0.000383	CcSEcCtD
Sunitinib—Hepatobiliary disease—Doxorubicin—urinary bladder cancer	3.85e-05	0.000381	CcSEcCtD
Sunitinib—Epistaxis—Doxorubicin—urinary bladder cancer	3.84e-05	0.00038	CcSEcCtD
Sunitinib—Angiopathy—Methotrexate—urinary bladder cancer	3.83e-05	0.000379	CcSEcCtD
Sunitinib—Immune system disorder—Methotrexate—urinary bladder cancer	3.82e-05	0.000377	CcSEcCtD
Sunitinib—Dizziness—Fluorouracil—urinary bladder cancer	3.82e-05	0.000377	CcSEcCtD
Sunitinib—PLK4—Idarubicin—Doxorubicin—urinary bladder cancer	3.81e-05	0.0128	CbGdCrCtD
Sunitinib—PLK4—Epirubicin—Doxorubicin—urinary bladder cancer	3.81e-05	0.0128	CbGdCrCtD
Sunitinib—Mediastinal disorder—Methotrexate—urinary bladder cancer	3.81e-05	0.000376	CcSEcCtD
Sunitinib—Chills—Methotrexate—urinary bladder cancer	3.79e-05	0.000374	CcSEcCtD
Sunitinib—Diarrhoea—Cisplatin—urinary bladder cancer	3.74e-05	0.00037	CcSEcCtD
Sunitinib—Erythema multiforme—Epirubicin—urinary bladder cancer	3.74e-05	0.000369	CcSEcCtD
Sunitinib—Alopecia—Methotrexate—urinary bladder cancer	3.73e-05	0.000369	CcSEcCtD
Sunitinib—Vomiting—Gemcitabine—urinary bladder cancer	3.73e-05	0.000369	CcSEcCtD
Sunitinib—Bradycardia—Doxorubicin—urinary bladder cancer	3.73e-05	0.000368	CcSEcCtD
Sunitinib—Mental disorder—Methotrexate—urinary bladder cancer	3.7e-05	0.000366	CcSEcCtD
Sunitinib—Rash—Gemcitabine—urinary bladder cancer	3.7e-05	0.000366	CcSEcCtD
Sunitinib—Dermatitis—Gemcitabine—urinary bladder cancer	3.7e-05	0.000365	CcSEcCtD
Sunitinib—Eye disorder—Epirubicin—urinary bladder cancer	3.7e-05	0.000365	CcSEcCtD
Sunitinib—Hypersensitivity—Etoposide—urinary bladder cancer	3.69e-05	0.000365	CcSEcCtD
Sunitinib—Malnutrition—Methotrexate—urinary bladder cancer	3.68e-05	0.000363	CcSEcCtD
Sunitinib—Erythema—Methotrexate—urinary bladder cancer	3.68e-05	0.000363	CcSEcCtD
Sunitinib—Haemoglobin—Doxorubicin—urinary bladder cancer	3.68e-05	0.000363	CcSEcCtD
Sunitinib—Headache—Gemcitabine—urinary bladder cancer	3.68e-05	0.000363	CcSEcCtD
Sunitinib—Flushing—Epirubicin—urinary bladder cancer	3.67e-05	0.000362	CcSEcCtD
Sunitinib—Cardiac disorder—Epirubicin—urinary bladder cancer	3.67e-05	0.000362	CcSEcCtD
Sunitinib—Vomiting—Fluorouracil—urinary bladder cancer	3.67e-05	0.000362	CcSEcCtD
Sunitinib—Hepatitis—Doxorubicin—urinary bladder cancer	3.66e-05	0.000361	CcSEcCtD
Sunitinib—Haemorrhage—Doxorubicin—urinary bladder cancer	3.66e-05	0.000361	CcSEcCtD
Sunitinib—Hypoaesthesia—Doxorubicin—urinary bladder cancer	3.64e-05	0.00036	CcSEcCtD
Sunitinib—Rash—Fluorouracil—urinary bladder cancer	3.64e-05	0.000359	CcSEcCtD
Sunitinib—Dermatitis—Fluorouracil—urinary bladder cancer	3.64e-05	0.000359	CcSEcCtD
Sunitinib—CHEK2—Doxorubicin—Epirubicin—urinary bladder cancer	3.63e-05	0.0122	CbGdCrCtD
Sunitinib—Headache—Fluorouracil—urinary bladder cancer	3.62e-05	0.000357	CcSEcCtD
Sunitinib—Urinary tract disorder—Doxorubicin—urinary bladder cancer	3.61e-05	0.000357	CcSEcCtD
Sunitinib—Oedema peripheral—Doxorubicin—urinary bladder cancer	3.6e-05	0.000356	CcSEcCtD
Sunitinib—Dysgeusia—Methotrexate—urinary bladder cancer	3.6e-05	0.000356	CcSEcCtD
Sunitinib—Asthenia—Etoposide—urinary bladder cancer	3.6e-05	0.000355	CcSEcCtD
Sunitinib—Connective tissue disorder—Doxorubicin—urinary bladder cancer	3.6e-05	0.000355	CcSEcCtD
Sunitinib—Angiopathy—Epirubicin—urinary bladder cancer	3.59e-05	0.000354	CcSEcCtD
Sunitinib—Urethral disorder—Doxorubicin—urinary bladder cancer	3.59e-05	0.000354	CcSEcCtD
Sunitinib—ABCG2—vagina—urinary bladder cancer	3.59e-05	0.000337	CbGeAlD
Sunitinib—ABCB1—prostate gland—urinary bladder cancer	3.58e-05	0.000337	CbGeAlD
Sunitinib—Immune system disorder—Epirubicin—urinary bladder cancer	3.57e-05	0.000353	CcSEcCtD
Sunitinib—Mediastinal disorder—Epirubicin—urinary bladder cancer	3.56e-05	0.000352	CcSEcCtD
Sunitinib—Back pain—Methotrexate—urinary bladder cancer	3.56e-05	0.000351	CcSEcCtD
Sunitinib—Chills—Epirubicin—urinary bladder cancer	3.55e-05	0.00035	CcSEcCtD
Sunitinib—Pruritus—Etoposide—urinary bladder cancer	3.55e-05	0.00035	CcSEcCtD
Sunitinib—Arrhythmia—Epirubicin—urinary bladder cancer	3.53e-05	0.000349	CcSEcCtD
Sunitinib—Alopecia—Epirubicin—urinary bladder cancer	3.49e-05	0.000345	CcSEcCtD
Sunitinib—Nausea—Gemcitabine—urinary bladder cancer	3.49e-05	0.000344	CcSEcCtD
Sunitinib—Vomiting—Cisplatin—urinary bladder cancer	3.48e-05	0.000344	CcSEcCtD
Sunitinib—Mental disorder—Epirubicin—urinary bladder cancer	3.46e-05	0.000342	CcSEcCtD
Sunitinib—Erythema multiforme—Doxorubicin—urinary bladder cancer	3.46e-05	0.000342	CcSEcCtD
Sunitinib—Rash—Cisplatin—urinary bladder cancer	3.45e-05	0.000341	CcSEcCtD
Sunitinib—CYP3A4—renal system—urinary bladder cancer	3.45e-05	0.000325	CbGeAlD
Sunitinib—Dermatitis—Cisplatin—urinary bladder cancer	3.45e-05	0.00034	CcSEcCtD
Sunitinib—Erythema—Epirubicin—urinary bladder cancer	3.44e-05	0.00034	CcSEcCtD
Sunitinib—Malnutrition—Epirubicin—urinary bladder cancer	3.44e-05	0.00034	CcSEcCtD
Sunitinib—Diarrhoea—Etoposide—urinary bladder cancer	3.43e-05	0.000339	CcSEcCtD
Sunitinib—Nausea—Fluorouracil—urinary bladder cancer	3.43e-05	0.000339	CcSEcCtD
Sunitinib—Eye disorder—Doxorubicin—urinary bladder cancer	3.42e-05	0.000338	CcSEcCtD
Sunitinib—Anaemia—Methotrexate—urinary bladder cancer	3.4e-05	0.000336	CcSEcCtD
Sunitinib—Flushing—Doxorubicin—urinary bladder cancer	3.4e-05	0.000335	CcSEcCtD
Sunitinib—Cardiac disorder—Doxorubicin—urinary bladder cancer	3.4e-05	0.000335	CcSEcCtD
Sunitinib—Flatulence—Epirubicin—urinary bladder cancer	3.39e-05	0.000335	CcSEcCtD
Sunitinib—Dysgeusia—Epirubicin—urinary bladder cancer	3.37e-05	0.000333	CcSEcCtD
Sunitinib—CHEK2—Epirubicin—Doxorubicin—urinary bladder cancer	3.36e-05	0.0113	CbGdCrCtD
Sunitinib—Back pain—Epirubicin—urinary bladder cancer	3.33e-05	0.000329	CcSEcCtD
Sunitinib—CYP3A5—vagina—urinary bladder cancer	3.33e-05	0.000313	CbGeAlD
Sunitinib—Angiopathy—Doxorubicin—urinary bladder cancer	3.32e-05	0.000328	CcSEcCtD
Sunitinib—Dizziness—Etoposide—urinary bladder cancer	3.31e-05	0.000327	CcSEcCtD
Sunitinib—Muscle spasms—Epirubicin—urinary bladder cancer	3.31e-05	0.000327	CcSEcCtD
Sunitinib—Immune system disorder—Doxorubicin—urinary bladder cancer	3.31e-05	0.000326	CcSEcCtD
Sunitinib—Mediastinal disorder—Doxorubicin—urinary bladder cancer	3.3e-05	0.000326	CcSEcCtD
Sunitinib—Leukopenia—Methotrexate—urinary bladder cancer	3.29e-05	0.000325	CcSEcCtD
Sunitinib—ABCC4—lymph node—urinary bladder cancer	3.29e-05	0.000309	CbGeAlD
Sunitinib—Chills—Doxorubicin—urinary bladder cancer	3.28e-05	0.000324	CcSEcCtD
Sunitinib—Arrhythmia—Doxorubicin—urinary bladder cancer	3.27e-05	0.000323	CcSEcCtD
Sunitinib—Nausea—Cisplatin—urinary bladder cancer	3.25e-05	0.000321	CcSEcCtD
Sunitinib—Alopecia—Doxorubicin—urinary bladder cancer	3.23e-05	0.000319	CcSEcCtD
Sunitinib—Cough—Methotrexate—urinary bladder cancer	3.21e-05	0.000317	CcSEcCtD
Sunitinib—Mental disorder—Doxorubicin—urinary bladder cancer	3.21e-05	0.000317	CcSEcCtD
Sunitinib—Convulsion—Methotrexate—urinary bladder cancer	3.19e-05	0.000315	CcSEcCtD
Sunitinib—Vomiting—Etoposide—urinary bladder cancer	3.19e-05	0.000315	CcSEcCtD
Sunitinib—Erythema—Doxorubicin—urinary bladder cancer	3.19e-05	0.000315	CcSEcCtD
Sunitinib—Malnutrition—Doxorubicin—urinary bladder cancer	3.19e-05	0.000315	CcSEcCtD
Sunitinib—Anaemia—Epirubicin—urinary bladder cancer	3.18e-05	0.000314	CcSEcCtD
Sunitinib—ABCC2—lymph node—urinary bladder cancer	3.18e-05	0.000299	CbGeAlD
Sunitinib—Rash—Etoposide—urinary bladder cancer	3.16e-05	0.000312	CcSEcCtD
Sunitinib—Dermatitis—Etoposide—urinary bladder cancer	3.16e-05	0.000312	CcSEcCtD
Sunitinib—Headache—Etoposide—urinary bladder cancer	3.14e-05	0.00031	CcSEcCtD
Sunitinib—Flatulence—Doxorubicin—urinary bladder cancer	3.14e-05	0.00031	CcSEcCtD
Sunitinib—Myalgia—Methotrexate—urinary bladder cancer	3.13e-05	0.000309	CcSEcCtD
Sunitinib—Arthralgia—Methotrexate—urinary bladder cancer	3.13e-05	0.000309	CcSEcCtD
Sunitinib—Chest pain—Methotrexate—urinary bladder cancer	3.13e-05	0.000309	CcSEcCtD
Sunitinib—Dysgeusia—Doxorubicin—urinary bladder cancer	3.12e-05	0.000308	CcSEcCtD
Sunitinib—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—urinary bladder cancer	3.11e-05	0.000307	CcSEcCtD
Sunitinib—Leukopenia—Epirubicin—urinary bladder cancer	3.08e-05	0.000304	CcSEcCtD
Sunitinib—Back pain—Doxorubicin—urinary bladder cancer	3.08e-05	0.000304	CcSEcCtD
Sunitinib—Muscle spasms—Doxorubicin—urinary bladder cancer	3.06e-05	0.000302	CcSEcCtD
Sunitinib—ABCB1—seminal vesicle—urinary bladder cancer	3.03e-05	0.000285	CbGeAlD
Sunitinib—Cough—Epirubicin—urinary bladder cancer	3e-05	0.000297	CcSEcCtD
Sunitinib—Convulsion—Epirubicin—urinary bladder cancer	2.98e-05	0.000295	CcSEcCtD
Sunitinib—Infection—Methotrexate—urinary bladder cancer	2.98e-05	0.000295	CcSEcCtD
Sunitinib—Nausea—Etoposide—urinary bladder cancer	2.98e-05	0.000294	CcSEcCtD
Sunitinib—Hypertension—Epirubicin—urinary bladder cancer	2.97e-05	0.000294	CcSEcCtD
Sunitinib—Nervous system disorder—Methotrexate—urinary bladder cancer	2.94e-05	0.000291	CcSEcCtD
Sunitinib—Anaemia—Doxorubicin—urinary bladder cancer	2.94e-05	0.000291	CcSEcCtD
Sunitinib—Thrombocytopenia—Methotrexate—urinary bladder cancer	2.94e-05	0.00029	CcSEcCtD
Sunitinib—Myalgia—Epirubicin—urinary bladder cancer	2.93e-05	0.000289	CcSEcCtD
Sunitinib—Chest pain—Epirubicin—urinary bladder cancer	2.93e-05	0.000289	CcSEcCtD
Sunitinib—Arthralgia—Epirubicin—urinary bladder cancer	2.93e-05	0.000289	CcSEcCtD
Sunitinib—Skin disorder—Methotrexate—urinary bladder cancer	2.92e-05	0.000288	CcSEcCtD
Sunitinib—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—urinary bladder cancer	2.91e-05	0.000287	CcSEcCtD
Sunitinib—Dry mouth—Epirubicin—urinary bladder cancer	2.87e-05	0.000283	CcSEcCtD
Sunitinib—Anorexia—Methotrexate—urinary bladder cancer	2.86e-05	0.000283	CcSEcCtD
Sunitinib—Leukopenia—Doxorubicin—urinary bladder cancer	2.85e-05	0.000282	CcSEcCtD
Sunitinib—Oedema—Epirubicin—urinary bladder cancer	2.81e-05	0.000277	CcSEcCtD
Sunitinib—Infection—Epirubicin—urinary bladder cancer	2.79e-05	0.000276	CcSEcCtD
Sunitinib—Cough—Doxorubicin—urinary bladder cancer	2.78e-05	0.000275	CcSEcCtD
Sunitinib—Shock—Epirubicin—urinary bladder cancer	2.76e-05	0.000273	CcSEcCtD
Sunitinib—CYP3A4—female reproductive system—urinary bladder cancer	2.76e-05	0.00026	CbGeAlD
Sunitinib—Convulsion—Doxorubicin—urinary bladder cancer	2.76e-05	0.000273	CcSEcCtD
Sunitinib—Nervous system disorder—Epirubicin—urinary bladder cancer	2.76e-05	0.000272	CcSEcCtD
Sunitinib—Thrombocytopenia—Epirubicin—urinary bladder cancer	2.75e-05	0.000272	CcSEcCtD
Sunitinib—Hypertension—Doxorubicin—urinary bladder cancer	2.75e-05	0.000272	CcSEcCtD
Sunitinib—Musculoskeletal discomfort—Methotrexate—urinary bladder cancer	2.74e-05	0.00027	CcSEcCtD
Sunitinib—Skin disorder—Epirubicin—urinary bladder cancer	2.73e-05	0.00027	CcSEcCtD
Sunitinib—Insomnia—Methotrexate—urinary bladder cancer	2.72e-05	0.000268	CcSEcCtD
Sunitinib—Myalgia—Doxorubicin—urinary bladder cancer	2.71e-05	0.000268	CcSEcCtD
Sunitinib—Chest pain—Doxorubicin—urinary bladder cancer	2.71e-05	0.000268	CcSEcCtD
Sunitinib—Arthralgia—Doxorubicin—urinary bladder cancer	2.71e-05	0.000268	CcSEcCtD
Sunitinib—Paraesthesia—Methotrexate—urinary bladder cancer	2.7e-05	0.000266	CcSEcCtD
Sunitinib—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—urinary bladder cancer	2.69e-05	0.000266	CcSEcCtD
Sunitinib—Anorexia—Epirubicin—urinary bladder cancer	2.68e-05	0.000264	CcSEcCtD
Sunitinib—Dyspnoea—Methotrexate—urinary bladder cancer	2.68e-05	0.000264	CcSEcCtD
Sunitinib—Dry mouth—Doxorubicin—urinary bladder cancer	2.65e-05	0.000262	CcSEcCtD
Sunitinib—Dyspepsia—Methotrexate—urinary bladder cancer	2.64e-05	0.000261	CcSEcCtD
Sunitinib—ABCB1—epithelium—urinary bladder cancer	2.63e-05	0.000248	CbGeAlD
Sunitinib—Decreased appetite—Methotrexate—urinary bladder cancer	2.61e-05	0.000258	CcSEcCtD
Sunitinib—KCNH2—lymph node—urinary bladder cancer	2.61e-05	0.000245	CbGeAlD
Sunitinib—Oedema—Doxorubicin—urinary bladder cancer	2.6e-05	0.000257	CcSEcCtD
Sunitinib—Gastrointestinal disorder—Methotrexate—urinary bladder cancer	2.59e-05	0.000256	CcSEcCtD
Sunitinib—Fatigue—Methotrexate—urinary bladder cancer	2.59e-05	0.000256	CcSEcCtD
Sunitinib—Infection—Doxorubicin—urinary bladder cancer	2.58e-05	0.000255	CcSEcCtD
Sunitinib—Pain—Methotrexate—urinary bladder cancer	2.57e-05	0.000254	CcSEcCtD
Sunitinib—Musculoskeletal discomfort—Epirubicin—urinary bladder cancer	2.56e-05	0.000253	CcSEcCtD
Sunitinib—Shock—Doxorubicin—urinary bladder cancer	2.56e-05	0.000253	CcSEcCtD
Sunitinib—Nervous system disorder—Doxorubicin—urinary bladder cancer	2.55e-05	0.000252	CcSEcCtD
Sunitinib—Thrombocytopenia—Doxorubicin—urinary bladder cancer	2.55e-05	0.000251	CcSEcCtD
Sunitinib—Insomnia—Epirubicin—urinary bladder cancer	2.54e-05	0.000251	CcSEcCtD
Sunitinib—Skin disorder—Doxorubicin—urinary bladder cancer	2.53e-05	0.000249	CcSEcCtD
Sunitinib—Paraesthesia—Epirubicin—urinary bladder cancer	2.52e-05	0.000249	CcSEcCtD
Sunitinib—Dyspnoea—Epirubicin—urinary bladder cancer	2.5e-05	0.000247	CcSEcCtD
Sunitinib—Anorexia—Doxorubicin—urinary bladder cancer	2.48e-05	0.000245	CcSEcCtD
Sunitinib—Dyspepsia—Epirubicin—urinary bladder cancer	2.47e-05	0.000244	CcSEcCtD
Sunitinib—Gastrointestinal pain—Methotrexate—urinary bladder cancer	2.45e-05	0.000242	CcSEcCtD
Sunitinib—Decreased appetite—Epirubicin—urinary bladder cancer	2.44e-05	0.000241	CcSEcCtD
Sunitinib—ABCB1—renal system—urinary bladder cancer	2.44e-05	0.00023	CbGeAlD
Sunitinib—Gastrointestinal disorder—Epirubicin—urinary bladder cancer	2.43e-05	0.00024	CcSEcCtD
Sunitinib—Fatigue—Epirubicin—urinary bladder cancer	2.42e-05	0.000239	CcSEcCtD
Sunitinib—Constipation—Epirubicin—urinary bladder cancer	2.4e-05	0.000237	CcSEcCtD
Sunitinib—Pain—Epirubicin—urinary bladder cancer	2.4e-05	0.000237	CcSEcCtD
Sunitinib—ABCB1—urethra—urinary bladder cancer	2.4e-05	0.000226	CbGeAlD
Sunitinib—Body temperature increased—Methotrexate—urinary bladder cancer	2.37e-05	0.000234	CcSEcCtD
Sunitinib—Abdominal pain—Methotrexate—urinary bladder cancer	2.37e-05	0.000234	CcSEcCtD
Sunitinib—Musculoskeletal discomfort—Doxorubicin—urinary bladder cancer	2.37e-05	0.000234	CcSEcCtD
Sunitinib—Insomnia—Doxorubicin—urinary bladder cancer	2.35e-05	0.000232	CcSEcCtD
Sunitinib—Paraesthesia—Doxorubicin—urinary bladder cancer	2.33e-05	0.000231	CcSEcCtD
Sunitinib—ABCG2—lymph node—urinary bladder cancer	2.32e-05	0.000218	CbGeAlD
Sunitinib—Dyspnoea—Doxorubicin—urinary bladder cancer	2.32e-05	0.000229	CcSEcCtD
Sunitinib—Gastrointestinal pain—Epirubicin—urinary bladder cancer	2.3e-05	0.000227	CcSEcCtD
Sunitinib—Dyspepsia—Doxorubicin—urinary bladder cancer	2.29e-05	0.000226	CcSEcCtD
Sunitinib—Decreased appetite—Doxorubicin—urinary bladder cancer	2.26e-05	0.000223	CcSEcCtD
Sunitinib—Gastrointestinal disorder—Doxorubicin—urinary bladder cancer	2.24e-05	0.000222	CcSEcCtD
Sunitinib—Fatigue—Doxorubicin—urinary bladder cancer	2.24e-05	0.000221	CcSEcCtD
Sunitinib—Pain—Doxorubicin—urinary bladder cancer	2.22e-05	0.00022	CcSEcCtD
Sunitinib—Constipation—Doxorubicin—urinary bladder cancer	2.22e-05	0.00022	CcSEcCtD
Sunitinib—Abdominal pain—Epirubicin—urinary bladder cancer	2.22e-05	0.000219	CcSEcCtD
Sunitinib—Body temperature increased—Epirubicin—urinary bladder cancer	2.22e-05	0.000219	CcSEcCtD
Sunitinib—Hypersensitivity—Methotrexate—urinary bladder cancer	2.21e-05	0.000218	CcSEcCtD
Sunitinib—Asthenia—Methotrexate—urinary bladder cancer	2.15e-05	0.000213	CcSEcCtD
Sunitinib—Gastrointestinal pain—Doxorubicin—urinary bladder cancer	2.13e-05	0.00021	CcSEcCtD
Sunitinib—Pruritus—Methotrexate—urinary bladder cancer	2.12e-05	0.00021	CcSEcCtD
Sunitinib—Hypersensitivity—Epirubicin—urinary bladder cancer	2.07e-05	0.000204	CcSEcCtD
Sunitinib—Abdominal pain—Doxorubicin—urinary bladder cancer	2.06e-05	0.000203	CcSEcCtD
Sunitinib—Body temperature increased—Doxorubicin—urinary bladder cancer	2.06e-05	0.000203	CcSEcCtD
Sunitinib—Diarrhoea—Methotrexate—urinary bladder cancer	2.05e-05	0.000203	CcSEcCtD
Sunitinib—Asthenia—Epirubicin—urinary bladder cancer	2.02e-05	0.000199	CcSEcCtD
Sunitinib—Pruritus—Epirubicin—urinary bladder cancer	1.99e-05	0.000196	CcSEcCtD
Sunitinib—Dizziness—Methotrexate—urinary bladder cancer	1.99e-05	0.000196	CcSEcCtD
Sunitinib—ABCB1—female reproductive system—urinary bladder cancer	1.96e-05	0.000184	CbGeAlD
Sunitinib—Diarrhoea—Epirubicin—urinary bladder cancer	1.92e-05	0.00019	CcSEcCtD
Sunitinib—Hypersensitivity—Doxorubicin—urinary bladder cancer	1.92e-05	0.000189	CcSEcCtD
Sunitinib—Vomiting—Methotrexate—urinary bladder cancer	1.91e-05	0.000189	CcSEcCtD
Sunitinib—Rash—Methotrexate—urinary bladder cancer	1.89e-05	0.000187	CcSEcCtD
Sunitinib—Dermatitis—Methotrexate—urinary bladder cancer	1.89e-05	0.000187	CcSEcCtD
Sunitinib—Headache—Methotrexate—urinary bladder cancer	1.88e-05	0.000186	CcSEcCtD
Sunitinib—Asthenia—Doxorubicin—urinary bladder cancer	1.87e-05	0.000184	CcSEcCtD
Sunitinib—Dizziness—Epirubicin—urinary bladder cancer	1.86e-05	0.000183	CcSEcCtD
Sunitinib—Pruritus—Doxorubicin—urinary bladder cancer	1.84e-05	0.000182	CcSEcCtD
Sunitinib—Vomiting—Epirubicin—urinary bladder cancer	1.79e-05	0.000176	CcSEcCtD
Sunitinib—Nausea—Methotrexate—urinary bladder cancer	1.78e-05	0.000176	CcSEcCtD
Sunitinib—Diarrhoea—Doxorubicin—urinary bladder cancer	1.78e-05	0.000176	CcSEcCtD
Sunitinib—Rash—Epirubicin—urinary bladder cancer	1.77e-05	0.000175	CcSEcCtD
Sunitinib—Dermatitis—Epirubicin—urinary bladder cancer	1.77e-05	0.000175	CcSEcCtD
Sunitinib—ABCB1—vagina—urinary bladder cancer	1.77e-05	0.000166	CbGeAlD
Sunitinib—Headache—Epirubicin—urinary bladder cancer	1.76e-05	0.000174	CcSEcCtD
Sunitinib—Dizziness—Doxorubicin—urinary bladder cancer	1.72e-05	0.00017	CcSEcCtD
Sunitinib—Nausea—Epirubicin—urinary bladder cancer	1.67e-05	0.000165	CcSEcCtD
Sunitinib—Vomiting—Doxorubicin—urinary bladder cancer	1.65e-05	0.000163	CcSEcCtD
Sunitinib—Rash—Doxorubicin—urinary bladder cancer	1.64e-05	0.000162	CcSEcCtD
Sunitinib—Dermatitis—Doxorubicin—urinary bladder cancer	1.64e-05	0.000162	CcSEcCtD
Sunitinib—Headache—Doxorubicin—urinary bladder cancer	1.63e-05	0.000161	CcSEcCtD
Sunitinib—Nausea—Doxorubicin—urinary bladder cancer	1.54e-05	0.000153	CcSEcCtD
Sunitinib—ABCB1—lymph node—urinary bladder cancer	1.14e-05	0.000108	CbGeAlD
Sunitinib—JAK2—Disease—SRC—urinary bladder cancer	7.42e-07	5.6e-06	CbGpPWpGaD
Sunitinib—FYN—Immune System—EGFR—urinary bladder cancer	7.41e-07	5.59e-06	CbGpPWpGaD
Sunitinib—TYK2—Signaling Pathways—CDKN1A—urinary bladder cancer	7.41e-07	5.59e-06	CbGpPWpGaD
Sunitinib—TYK2—Signaling Pathways—PTEN—urinary bladder cancer	7.39e-07	5.58e-06	CbGpPWpGaD
Sunitinib—MAP2K1—Immune System—EGFR—urinary bladder cancer	7.37e-07	5.56e-06	CbGpPWpGaD
Sunitinib—FGFR2—Immune System—HRAS—urinary bladder cancer	7.37e-07	5.56e-06	CbGpPWpGaD
Sunitinib—PRKAA1—Signaling Pathways—HRAS—urinary bladder cancer	7.35e-07	5.54e-06	CbGpPWpGaD
Sunitinib—MAP2K2—Signaling Pathways—ERBB2—urinary bladder cancer	7.35e-07	5.54e-06	CbGpPWpGaD
Sunitinib—FGFR2—Signaling Pathways—MMP9—urinary bladder cancer	7.34e-07	5.54e-06	CbGpPWpGaD
Sunitinib—CYP3A5—Metabolism—MTHFR—urinary bladder cancer	7.32e-07	5.52e-06	CbGpPWpGaD
Sunitinib—FGFR2—Signaling Pathways—CDKN1A—urinary bladder cancer	7.32e-07	5.52e-06	CbGpPWpGaD
Sunitinib—FGFR2—Signaling Pathways—PTEN—urinary bladder cancer	7.3e-07	5.51e-06	CbGpPWpGaD
Sunitinib—RPS6KB1—Signaling Pathways—KRAS—urinary bladder cancer	7.29e-07	5.5e-06	CbGpPWpGaD
Sunitinib—MAP2K5—Signaling Pathways—KRAS—urinary bladder cancer	7.29e-07	5.5e-06	CbGpPWpGaD
Sunitinib—RPS6KA3—Signaling Pathways—HRAS—urinary bladder cancer	7.28e-07	5.49e-06	CbGpPWpGaD
Sunitinib—JAK2—Signaling by GPCR—KRAS—urinary bladder cancer	7.28e-07	5.49e-06	CbGpPWpGaD
Sunitinib—MAP2K2—Disease—EGFR—urinary bladder cancer	7.27e-07	5.49e-06	CbGpPWpGaD
Sunitinib—IRAK1—Signaling Pathways—EP300—urinary bladder cancer	7.26e-07	5.48e-06	CbGpPWpGaD
Sunitinib—PDGFRB—Immune System—KRAS—urinary bladder cancer	7.26e-07	5.48e-06	CbGpPWpGaD
Sunitinib—PDGFRB—Disease—MYC—urinary bladder cancer	7.26e-07	5.47e-06	CbGpPWpGaD
Sunitinib—MAP3K7—Immune System—HRAS—urinary bladder cancer	7.24e-07	5.46e-06	CbGpPWpGaD
Sunitinib—KIT—Immune System—HRAS—urinary bladder cancer	7.24e-07	5.46e-06	CbGpPWpGaD
Sunitinib—FGFR1—Signaling Pathways—IL2—urinary bladder cancer	7.23e-07	5.45e-06	CbGpPWpGaD
Sunitinib—PDGFRA—Signaling Pathways—IL2—urinary bladder cancer	7.21e-07	5.44e-06	CbGpPWpGaD
Sunitinib—MAP3K7—Signaling Pathways—MMP9—urinary bladder cancer	7.21e-07	5.44e-06	CbGpPWpGaD
Sunitinib—KIT—Signaling Pathways—MMP9—urinary bladder cancer	7.21e-07	5.44e-06	CbGpPWpGaD
Sunitinib—MAP3K7—Signaling Pathways—CDKN1A—urinary bladder cancer	7.19e-07	5.42e-06	CbGpPWpGaD
Sunitinib—KIT—Signaling Pathways—CDKN1A—urinary bladder cancer	7.19e-07	5.42e-06	CbGpPWpGaD
Sunitinib—PDGFRB—Signaling Pathways—ERBB2—urinary bladder cancer	7.17e-07	5.41e-06	CbGpPWpGaD
Sunitinib—MAP3K7—Signaling Pathways—PTEN—urinary bladder cancer	7.17e-07	5.41e-06	CbGpPWpGaD
Sunitinib—KIT—Signaling Pathways—PTEN—urinary bladder cancer	7.17e-07	5.41e-06	CbGpPWpGaD
Sunitinib—KDR—Signaling Pathways—KRAS—urinary bladder cancer	7.1e-07	5.36e-06	CbGpPWpGaD
Sunitinib—PDGFRB—Disease—EGFR—urinary bladder cancer	7.1e-07	5.35e-06	CbGpPWpGaD
Sunitinib—JAK2—Signaling Pathways—RHOA—urinary bladder cancer	7.1e-07	5.35e-06	CbGpPWpGaD
Sunitinib—IRAK1—Signaling Pathways—SRC—urinary bladder cancer	7.06e-07	5.33e-06	CbGpPWpGaD
Sunitinib—FGFR1—Signaling Pathways—CCND1—urinary bladder cancer	7.05e-07	5.32e-06	CbGpPWpGaD
Sunitinib—TYK2—Signaling Pathways—EP300—urinary bladder cancer	7.05e-07	5.32e-06	CbGpPWpGaD
Sunitinib—JAK2—Immune System—EGFR—urinary bladder cancer	7.04e-07	5.31e-06	CbGpPWpGaD
Sunitinib—PDGFRA—Signaling Pathways—CCND1—urinary bladder cancer	7.03e-07	5.3e-06	CbGpPWpGaD
Sunitinib—FYN—Immune System—KRAS—urinary bladder cancer	7e-07	5.28e-06	CbGpPWpGaD
Sunitinib—FYN—Disease—MYC—urinary bladder cancer	6.99e-07	5.28e-06	CbGpPWpGaD
Sunitinib—PTK2B—Signaling Pathways—TP53—urinary bladder cancer	6.98e-07	5.26e-06	CbGpPWpGaD
Sunitinib—MAP2K2—Signaling Pathways—CXCL8—urinary bladder cancer	6.97e-07	5.26e-06	CbGpPWpGaD
Sunitinib—FGFR2—Signaling Pathways—EP300—urinary bladder cancer	6.96e-07	5.25e-06	CbGpPWpGaD
Sunitinib—MAP2K1—Immune System—KRAS—urinary bladder cancer	6.96e-07	5.25e-06	CbGpPWpGaD
Sunitinib—MAP2K1—Disease—MYC—urinary bladder cancer	6.96e-07	5.25e-06	CbGpPWpGaD
Sunitinib—MAP2K2—Signaling by GPCR—HRAS—urinary bladder cancer	6.92e-07	5.22e-06	CbGpPWpGaD
Sunitinib—FYN—Signaling Pathways—ERBB2—urinary bladder cancer	6.91e-07	5.21e-06	CbGpPWpGaD
Sunitinib—TYK2—Disease—HRAS—urinary bladder cancer	6.89e-07	5.2e-06	CbGpPWpGaD
Sunitinib—MAP2K1—Signaling Pathways—ERBB2—urinary bladder cancer	6.87e-07	5.19e-06	CbGpPWpGaD
Sunitinib—MAP2K2—Disease—KRAS—urinary bladder cancer	6.87e-07	5.18e-06	CbGpPWpGaD
Sunitinib—FGFR1—Immune System—HRAS—urinary bladder cancer	6.87e-07	5.18e-06	CbGpPWpGaD
Sunitinib—TYK2—Signaling Pathways—SRC—urinary bladder cancer	6.86e-07	5.17e-06	CbGpPWpGaD
Sunitinib—PDGFRA—Immune System—HRAS—urinary bladder cancer	6.85e-07	5.17e-06	CbGpPWpGaD
Sunitinib—FGFR1—Signaling Pathways—MMP9—urinary bladder cancer	6.84e-07	5.16e-06	CbGpPWpGaD
Sunitinib—FYN—Disease—EGFR—urinary bladder cancer	6.84e-07	5.16e-06	CbGpPWpGaD
Sunitinib—MAP3K7—Signaling Pathways—EP300—urinary bladder cancer	6.84e-07	5.16e-06	CbGpPWpGaD
Sunitinib—KIT—Signaling Pathways—EP300—urinary bladder cancer	6.84e-07	5.16e-06	CbGpPWpGaD
Sunitinib—PDGFRA—Signaling Pathways—MMP9—urinary bladder cancer	6.83e-07	5.15e-06	CbGpPWpGaD
Sunitinib—FGFR1—Signaling Pathways—CDKN1A—urinary bladder cancer	6.82e-07	5.14e-06	CbGpPWpGaD
Sunitinib—FGFR1—Signaling Pathways—PTEN—urinary bladder cancer	6.8e-07	5.13e-06	CbGpPWpGaD
Sunitinib—MAP2K1—Disease—EGFR—urinary bladder cancer	6.8e-07	5.13e-06	CbGpPWpGaD
Sunitinib—FGFR2—Disease—HRAS—urinary bladder cancer	6.8e-07	5.13e-06	CbGpPWpGaD
Sunitinib—ABCB1—Metabolism—GSTP1—urinary bladder cancer	6.8e-07	5.13e-06	CbGpPWpGaD
Sunitinib—PDGFRA—Signaling Pathways—CDKN1A—urinary bladder cancer	6.8e-07	5.13e-06	CbGpPWpGaD
Sunitinib—PDGFRB—Signaling Pathways—CXCL8—urinary bladder cancer	6.8e-07	5.13e-06	CbGpPWpGaD
Sunitinib—PDGFRA—Signaling Pathways—PTEN—urinary bladder cancer	6.79e-07	5.12e-06	CbGpPWpGaD
Sunitinib—FGFR2—Signaling Pathways—SRC—urinary bladder cancer	6.77e-07	5.11e-06	CbGpPWpGaD
Sunitinib—CYP3A4—Metabolism—RRM2—urinary bladder cancer	6.73e-07	5.08e-06	CbGpPWpGaD
Sunitinib—ROCK1—Signaling Pathways—TP53—urinary bladder cancer	6.72e-07	5.07e-06	CbGpPWpGaD
Sunitinib—PDGFRB—Disease—KRAS—urinary bladder cancer	6.7e-07	5.06e-06	CbGpPWpGaD
Sunitinib—KIT—Disease—HRAS—urinary bladder cancer	6.68e-07	5.04e-06	CbGpPWpGaD
Sunitinib—NTRK1—Signaling Pathways—TP53—urinary bladder cancer	6.68e-07	5.04e-06	CbGpPWpGaD
Sunitinib—PTK2B—Signaling Pathways—HRAS—urinary bladder cancer	6.67e-07	5.03e-06	CbGpPWpGaD
Sunitinib—YES1—Signaling Pathways—MYC—urinary bladder cancer	6.67e-07	5.03e-06	CbGpPWpGaD
Sunitinib—MAP2K2—Signaling Pathways—IL2—urinary bladder cancer	6.66e-07	5.02e-06	CbGpPWpGaD
Sunitinib—JAK2—Immune System—KRAS—urinary bladder cancer	6.65e-07	5.02e-06	CbGpPWpGaD
Sunitinib—MAP3K7—Signaling Pathways—SRC—urinary bladder cancer	6.65e-07	5.02e-06	CbGpPWpGaD
Sunitinib—KIT—Signaling Pathways—SRC—urinary bladder cancer	6.65e-07	5.02e-06	CbGpPWpGaD
Sunitinib—JAK2—Disease—MYC—urinary bladder cancer	6.65e-07	5.01e-06	CbGpPWpGaD
Sunitinib—JAK2—Signaling Pathways—ERBB2—urinary bladder cancer	6.57e-07	4.96e-06	CbGpPWpGaD
Sunitinib—FYN—Signaling Pathways—CXCL8—urinary bladder cancer	6.55e-07	4.94e-06	CbGpPWpGaD
Sunitinib—YES1—Signaling Pathways—EGFR—urinary bladder cancer	6.53e-07	4.92e-06	CbGpPWpGaD
Sunitinib—MAP2K1—Signaling Pathways—CXCL8—urinary bladder cancer	6.52e-07	4.92e-06	CbGpPWpGaD
Sunitinib—ABCG2—Metabolism—PTGS2—urinary bladder cancer	6.52e-07	4.92e-06	CbGpPWpGaD
Sunitinib—JAK2—Disease—EGFR—urinary bladder cancer	6.5e-07	4.9e-06	CbGpPWpGaD
Sunitinib—PDGFRB—Signaling Pathways—IL2—urinary bladder cancer	6.5e-07	4.9e-06	CbGpPWpGaD
Sunitinib—MAP2K2—Signaling Pathways—CCND1—urinary bladder cancer	6.49e-07	4.9e-06	CbGpPWpGaD
Sunitinib—FGFR1—Signaling Pathways—EP300—urinary bladder cancer	6.49e-07	4.89e-06	CbGpPWpGaD
Sunitinib—MAP2K1—Signaling by GPCR—HRAS—urinary bladder cancer	6.48e-07	4.89e-06	CbGpPWpGaD
Sunitinib—RPS6KB1—Signaling Pathways—TP53—urinary bladder cancer	6.48e-07	4.88e-06	CbGpPWpGaD
Sunitinib—MAP2K5—Signaling Pathways—TP53—urinary bladder cancer	6.48e-07	4.88e-06	CbGpPWpGaD
Sunitinib—PDGFRA—Signaling Pathways—EP300—urinary bladder cancer	6.47e-07	4.88e-06	CbGpPWpGaD
Sunitinib—FYN—Disease—KRAS—urinary bladder cancer	6.46e-07	4.87e-06	CbGpPWpGaD
Sunitinib—CYP3A7—Metabolism—PTGS2—urinary bladder cancer	6.46e-07	4.87e-06	CbGpPWpGaD
Sunitinib—ROCK1—Signaling Pathways—HRAS—urinary bladder cancer	6.43e-07	4.85e-06	CbGpPWpGaD
Sunitinib—MAP2K1—Disease—KRAS—urinary bladder cancer	6.43e-07	4.85e-06	CbGpPWpGaD
Sunitinib—NTRK1—Signaling Pathways—HRAS—urinary bladder cancer	6.39e-07	4.82e-06	CbGpPWpGaD
Sunitinib—FGFR1—Disease—HRAS—urinary bladder cancer	6.34e-07	4.78e-06	CbGpPWpGaD
Sunitinib—PDGFRB—Signaling Pathways—CCND1—urinary bladder cancer	6.33e-07	4.78e-06	CbGpPWpGaD
Sunitinib—IRAK1—Signaling Pathways—MYC—urinary bladder cancer	6.33e-07	4.77e-06	CbGpPWpGaD
Sunitinib—PDGFRA—Disease—HRAS—urinary bladder cancer	6.33e-07	4.77e-06	CbGpPWpGaD
Sunitinib—MAP2K2—Immune System—HRAS—urinary bladder cancer	6.33e-07	4.77e-06	CbGpPWpGaD
Sunitinib—ABCB1—Metabolism—TYMS—urinary bladder cancer	6.32e-07	4.77e-06	CbGpPWpGaD
Sunitinib—KDR—Signaling Pathways—TP53—urinary bladder cancer	6.31e-07	4.76e-06	CbGpPWpGaD
Sunitinib—FGFR1—Signaling Pathways—SRC—urinary bladder cancer	6.31e-07	4.76e-06	CbGpPWpGaD
Sunitinib—MAP2K2—Signaling Pathways—MMP9—urinary bladder cancer	6.3e-07	4.75e-06	CbGpPWpGaD
Sunitinib—PDGFRA—Signaling Pathways—SRC—urinary bladder cancer	6.29e-07	4.75e-06	CbGpPWpGaD
Sunitinib—MAP2K2—Signaling Pathways—CDKN1A—urinary bladder cancer	6.28e-07	4.74e-06	CbGpPWpGaD
Sunitinib—MAP2K2—Signaling Pathways—PTEN—urinary bladder cancer	6.27e-07	4.73e-06	CbGpPWpGaD
Sunitinib—FYN—Signaling Pathways—IL2—urinary bladder cancer	6.26e-07	4.72e-06	CbGpPWpGaD
Sunitinib—ABCB1—Metabolism—NCOR1—urinary bladder cancer	6.25e-07	4.72e-06	CbGpPWpGaD
Sunitinib—ABCB1—Metabolism—GSTM1—urinary bladder cancer	6.25e-07	4.72e-06	CbGpPWpGaD
Sunitinib—CYP3A4—Metabolism—ENO2—urinary bladder cancer	6.23e-07	4.7e-06	CbGpPWpGaD
Sunitinib—CYP3A4—Metabolism—HPGDS—urinary bladder cancer	6.23e-07	4.7e-06	CbGpPWpGaD
Sunitinib—JAK2—Signaling Pathways—CXCL8—urinary bladder cancer	6.23e-07	4.7e-06	CbGpPWpGaD
Sunitinib—MAP2K1—Signaling Pathways—IL2—urinary bladder cancer	6.23e-07	4.7e-06	CbGpPWpGaD
Sunitinib—RPS6KB1—Signaling Pathways—HRAS—urinary bladder cancer	6.19e-07	4.67e-06	CbGpPWpGaD
Sunitinib—MAP2K5—Signaling Pathways—HRAS—urinary bladder cancer	6.19e-07	4.67e-06	CbGpPWpGaD
Sunitinib—JAK2—Signaling by GPCR—HRAS—urinary bladder cancer	6.19e-07	4.67e-06	CbGpPWpGaD
Sunitinib—IRAK1—Signaling Pathways—EGFR—urinary bladder cancer	6.19e-07	4.67e-06	CbGpPWpGaD
Sunitinib—PDGFRB—Immune System—HRAS—urinary bladder cancer	6.17e-07	4.66e-06	CbGpPWpGaD
Sunitinib—YES1—Signaling Pathways—KRAS—urinary bladder cancer	6.16e-07	4.65e-06	CbGpPWpGaD
Sunitinib—PDGFRB—Signaling Pathways—MMP9—urinary bladder cancer	6.15e-07	4.64e-06	CbGpPWpGaD
Sunitinib—TYK2—Signaling Pathways—MYC—urinary bladder cancer	6.14e-07	4.63e-06	CbGpPWpGaD
Sunitinib—JAK2—Disease—KRAS—urinary bladder cancer	6.14e-07	4.63e-06	CbGpPWpGaD
Sunitinib—PDGFRB—Signaling Pathways—CDKN1A—urinary bladder cancer	6.13e-07	4.62e-06	CbGpPWpGaD
Sunitinib—PDGFRB—Signaling Pathways—PTEN—urinary bladder cancer	6.11e-07	4.61e-06	CbGpPWpGaD
Sunitinib—FYN—Signaling Pathways—CCND1—urinary bladder cancer	6.11e-07	4.61e-06	CbGpPWpGaD
Sunitinib—MAP2K1—Signaling Pathways—CCND1—urinary bladder cancer	6.07e-07	4.58e-06	CbGpPWpGaD
Sunitinib—FGFR2—Signaling Pathways—MYC—urinary bladder cancer	6.07e-07	4.58e-06	CbGpPWpGaD
Sunitinib—CYP3A4—Metabolism—GSTT1—urinary bladder cancer	6.05e-07	4.56e-06	CbGpPWpGaD
Sunitinib—KDR—Signaling Pathways—HRAS—urinary bladder cancer	6.04e-07	4.55e-06	CbGpPWpGaD
Sunitinib—TYK2—Signaling Pathways—EGFR—urinary bladder cancer	6.01e-07	4.53e-06	CbGpPWpGaD
Sunitinib—ABCB1—Metabolism—GPX1—urinary bladder cancer	5.99e-07	4.52e-06	CbGpPWpGaD
Sunitinib—MAP2K2—Signaling Pathways—EP300—urinary bladder cancer	5.98e-07	4.51e-06	CbGpPWpGaD
Sunitinib—MAP3K7—Signaling Pathways—MYC—urinary bladder cancer	5.96e-07	4.49e-06	CbGpPWpGaD
Sunitinib—KIT—Signaling Pathways—MYC—urinary bladder cancer	5.96e-07	4.49e-06	CbGpPWpGaD
Sunitinib—JAK2—Signaling Pathways—IL2—urinary bladder cancer	5.95e-07	4.49e-06	CbGpPWpGaD
Sunitinib—FYN—Immune System—HRAS—urinary bladder cancer	5.95e-07	4.49e-06	CbGpPWpGaD
Sunitinib—CYP3A5—Metabolism—PPARG—urinary bladder cancer	5.94e-07	4.48e-06	CbGpPWpGaD
Sunitinib—FGFR2—Signaling Pathways—EGFR—urinary bladder cancer	5.93e-07	4.48e-06	CbGpPWpGaD
Sunitinib—FYN—Signaling Pathways—MMP9—urinary bladder cancer	5.93e-07	4.47e-06	CbGpPWpGaD
Sunitinib—MAP2K1—Immune System—HRAS—urinary bladder cancer	5.92e-07	4.46e-06	CbGpPWpGaD
Sunitinib—FYN—Signaling Pathways—CDKN1A—urinary bladder cancer	5.91e-07	4.46e-06	CbGpPWpGaD
Sunitinib—MAP2K1—Signaling Pathways—MMP9—urinary bladder cancer	5.9e-07	4.45e-06	CbGpPWpGaD
Sunitinib—FYN—Signaling Pathways—PTEN—urinary bladder cancer	5.89e-07	4.45e-06	CbGpPWpGaD
Sunitinib—ABCB1—Metabolism—ERCC2—urinary bladder cancer	5.88e-07	4.43e-06	CbGpPWpGaD
Sunitinib—MAP2K1—Signaling Pathways—CDKN1A—urinary bladder cancer	5.88e-07	4.43e-06	CbGpPWpGaD
Sunitinib—MAP2K1—Signaling Pathways—PTEN—urinary bladder cancer	5.86e-07	4.42e-06	CbGpPWpGaD
Sunitinib—IRAK1—Signaling Pathways—KRAS—urinary bladder cancer	5.85e-07	4.41e-06	CbGpPWpGaD
Sunitinib—MAP2K2—Disease—HRAS—urinary bladder cancer	5.84e-07	4.4e-06	CbGpPWpGaD
Sunitinib—PDGFRB—Signaling Pathways—EP300—urinary bladder cancer	5.83e-07	4.4e-06	CbGpPWpGaD
Sunitinib—MAP3K7—Signaling Pathways—EGFR—urinary bladder cancer	5.83e-07	4.4e-06	CbGpPWpGaD
Sunitinib—KIT—Signaling Pathways—EGFR—urinary bladder cancer	5.83e-07	4.4e-06	CbGpPWpGaD
Sunitinib—MAP2K2—Signaling Pathways—SRC—urinary bladder cancer	5.81e-07	4.38e-06	CbGpPWpGaD
Sunitinib—JAK2—Signaling Pathways—CCND1—urinary bladder cancer	5.8e-07	4.38e-06	CbGpPWpGaD
Sunitinib—CYP3A5—Metabolism—CREBBP—urinary bladder cancer	5.7e-07	4.3e-06	CbGpPWpGaD
Sunitinib—PDGFRB—Disease—HRAS—urinary bladder cancer	5.7e-07	4.3e-06	CbGpPWpGaD
Sunitinib—ABCG2—Metabolism—PTEN—urinary bladder cancer	5.68e-07	4.29e-06	CbGpPWpGaD
Sunitinib—TYK2—Signaling Pathways—KRAS—urinary bladder cancer	5.68e-07	4.28e-06	CbGpPWpGaD
Sunitinib—PDGFRB—Signaling Pathways—SRC—urinary bladder cancer	5.67e-07	4.28e-06	CbGpPWpGaD
Sunitinib—JAK2—Immune System—HRAS—urinary bladder cancer	5.66e-07	4.27e-06	CbGpPWpGaD
Sunitinib—FGFR1—Signaling Pathways—MYC—urinary bladder cancer	5.65e-07	4.27e-06	CbGpPWpGaD
Sunitinib—PDGFRA—Signaling Pathways—MYC—urinary bladder cancer	5.64e-07	4.25e-06	CbGpPWpGaD
Sunitinib—JAK2—Signaling Pathways—MMP9—urinary bladder cancer	5.64e-07	4.25e-06	CbGpPWpGaD
Sunitinib—CYP3A7—Metabolism—PTEN—urinary bladder cancer	5.63e-07	4.25e-06	CbGpPWpGaD
Sunitinib—FYN—Signaling Pathways—EP300—urinary bladder cancer	5.62e-07	4.24e-06	CbGpPWpGaD
Sunitinib—JAK2—Signaling Pathways—CDKN1A—urinary bladder cancer	5.62e-07	4.24e-06	CbGpPWpGaD
Sunitinib—FGFR2—Signaling Pathways—KRAS—urinary bladder cancer	5.61e-07	4.23e-06	CbGpPWpGaD
Sunitinib—JAK2—Signaling Pathways—PTEN—urinary bladder cancer	5.6e-07	4.23e-06	CbGpPWpGaD
Sunitinib—MAP2K1—Signaling Pathways—EP300—urinary bladder cancer	5.59e-07	4.22e-06	CbGpPWpGaD
Sunitinib—FGFR1—Signaling Pathways—EGFR—urinary bladder cancer	5.53e-07	4.17e-06	CbGpPWpGaD
Sunitinib—ABCB1—Metabolism—MTHFR—urinary bladder cancer	5.52e-07	4.17e-06	CbGpPWpGaD
Sunitinib—PDGFRA—Signaling Pathways—EGFR—urinary bladder cancer	5.52e-07	4.16e-06	CbGpPWpGaD
Sunitinib—MAP3K7—Signaling Pathways—KRAS—urinary bladder cancer	5.51e-07	4.15e-06	CbGpPWpGaD
Sunitinib—KIT—Signaling Pathways—KRAS—urinary bladder cancer	5.51e-07	4.15e-06	CbGpPWpGaD
Sunitinib—FYN—Disease—HRAS—urinary bladder cancer	5.49e-07	4.14e-06	CbGpPWpGaD
Sunitinib—YES1—Signaling Pathways—TP53—urinary bladder cancer	5.48e-07	4.13e-06	CbGpPWpGaD
Sunitinib—FYN—Signaling Pathways—SRC—urinary bladder cancer	5.47e-07	4.12e-06	CbGpPWpGaD
Sunitinib—MAP2K1—Disease—HRAS—urinary bladder cancer	5.46e-07	4.12e-06	CbGpPWpGaD
Sunitinib—MAP2K1—Signaling Pathways—SRC—urinary bladder cancer	5.44e-07	4.1e-06	CbGpPWpGaD
Sunitinib—ABCG2—Metabolism—EP300—urinary bladder cancer	5.42e-07	4.09e-06	CbGpPWpGaD
Sunitinib—CYP3A7—Metabolism—EP300—urinary bladder cancer	5.37e-07	4.05e-06	CbGpPWpGaD
Sunitinib—JAK2—Signaling Pathways—EP300—urinary bladder cancer	5.34e-07	4.03e-06	CbGpPWpGaD
Sunitinib—YES1—Signaling Pathways—HRAS—urinary bladder cancer	5.24e-07	3.95e-06	CbGpPWpGaD
Sunitinib—FGFR1—Signaling Pathways—KRAS—urinary bladder cancer	5.22e-07	3.94e-06	CbGpPWpGaD
Sunitinib—JAK2—Disease—HRAS—urinary bladder cancer	5.22e-07	3.94e-06	CbGpPWpGaD
Sunitinib—PDGFRA—Signaling Pathways—KRAS—urinary bladder cancer	5.21e-07	3.93e-06	CbGpPWpGaD
Sunitinib—MAP2K2—Signaling Pathways—MYC—urinary bladder cancer	5.21e-07	3.93e-06	CbGpPWpGaD
Sunitinib—IRAK1—Signaling Pathways—TP53—urinary bladder cancer	5.2e-07	3.92e-06	CbGpPWpGaD
Sunitinib—JAK2—Signaling Pathways—SRC—urinary bladder cancer	5.2e-07	3.92e-06	CbGpPWpGaD
Sunitinib—MAP2K2—Signaling Pathways—EGFR—urinary bladder cancer	5.09e-07	3.84e-06	CbGpPWpGaD
Sunitinib—PDGFRB—Signaling Pathways—MYC—urinary bladder cancer	5.08e-07	3.83e-06	CbGpPWpGaD
Sunitinib—TYK2—Signaling Pathways—TP53—urinary bladder cancer	5.05e-07	3.81e-06	CbGpPWpGaD
Sunitinib—CYP3A4—Metabolism—NQO1—urinary bladder cancer	5.03e-07	3.79e-06	CbGpPWpGaD
Sunitinib—FGFR2—Signaling Pathways—TP53—urinary bladder cancer	4.98e-07	3.76e-06	CbGpPWpGaD
Sunitinib—PDGFRB—Signaling Pathways—EGFR—urinary bladder cancer	4.97e-07	3.75e-06	CbGpPWpGaD
Sunitinib—IRAK1—Signaling Pathways—HRAS—urinary bladder cancer	4.97e-07	3.75e-06	CbGpPWpGaD
Sunitinib—FYN—Signaling Pathways—MYC—urinary bladder cancer	4.9e-07	3.69e-06	CbGpPWpGaD
Sunitinib—KIT—Signaling Pathways—TP53—urinary bladder cancer	4.89e-07	3.69e-06	CbGpPWpGaD
Sunitinib—MAP3K7—Signaling Pathways—TP53—urinary bladder cancer	4.89e-07	3.69e-06	CbGpPWpGaD
Sunitinib—MAP2K1—Signaling Pathways—MYC—urinary bladder cancer	4.87e-07	3.67e-06	CbGpPWpGaD
Sunitinib—TYK2—Signaling Pathways—HRAS—urinary bladder cancer	4.82e-07	3.64e-06	CbGpPWpGaD
Sunitinib—MAP2K2—Signaling Pathways—KRAS—urinary bladder cancer	4.81e-07	3.63e-06	CbGpPWpGaD
Sunitinib—FYN—Signaling Pathways—EGFR—urinary bladder cancer	4.79e-07	3.61e-06	CbGpPWpGaD
Sunitinib—MAP2K1—Signaling Pathways—EGFR—urinary bladder cancer	4.76e-07	3.59e-06	CbGpPWpGaD
Sunitinib—FGFR2—Signaling Pathways—HRAS—urinary bladder cancer	4.76e-07	3.59e-06	CbGpPWpGaD
Sunitinib—PDGFRB—Signaling Pathways—KRAS—urinary bladder cancer	4.7e-07	3.54e-06	CbGpPWpGaD
Sunitinib—MAP3K7—Signaling Pathways—HRAS—urinary bladder cancer	4.68e-07	3.53e-06	CbGpPWpGaD
Sunitinib—KIT—Signaling Pathways—HRAS—urinary bladder cancer	4.68e-07	3.53e-06	CbGpPWpGaD
Sunitinib—CYP3A5—Metabolism—PTGS2—urinary bladder cancer	4.67e-07	3.52e-06	CbGpPWpGaD
Sunitinib—JAK2—Signaling Pathways—MYC—urinary bladder cancer	4.66e-07	3.51e-06	CbGpPWpGaD
Sunitinib—FGFR1—Signaling Pathways—TP53—urinary bladder cancer	4.64e-07	3.5e-06	CbGpPWpGaD
Sunitinib—PDGFRA—Signaling Pathways—TP53—urinary bladder cancer	4.63e-07	3.49e-06	CbGpPWpGaD
Sunitinib—JAK2—Signaling Pathways—EGFR—urinary bladder cancer	4.55e-07	3.43e-06	CbGpPWpGaD
Sunitinib—FYN—Signaling Pathways—KRAS—urinary bladder cancer	4.53e-07	3.41e-06	CbGpPWpGaD
Sunitinib—MAP2K1—Signaling Pathways—KRAS—urinary bladder cancer	4.5e-07	3.4e-06	CbGpPWpGaD
Sunitinib—ABCB1—Metabolism—PPARG—urinary bladder cancer	4.48e-07	3.38e-06	CbGpPWpGaD
Sunitinib—FGFR1—Signaling Pathways—HRAS—urinary bladder cancer	4.44e-07	3.35e-06	CbGpPWpGaD
Sunitinib—PDGFRA—Signaling Pathways—HRAS—urinary bladder cancer	4.43e-07	3.34e-06	CbGpPWpGaD
Sunitinib—ABCB1—Metabolism—CREBBP—urinary bladder cancer	4.3e-07	3.25e-06	CbGpPWpGaD
Sunitinib—JAK2—Signaling Pathways—KRAS—urinary bladder cancer	4.3e-07	3.24e-06	CbGpPWpGaD
Sunitinib—MAP2K2—Signaling Pathways—TP53—urinary bladder cancer	4.28e-07	3.23e-06	CbGpPWpGaD
Sunitinib—CYP3A4—Metabolism—GSTP1—urinary bladder cancer	4.19e-07	3.16e-06	CbGpPWpGaD
Sunitinib—PDGFRB—Signaling Pathways—TP53—urinary bladder cancer	4.17e-07	3.15e-06	CbGpPWpGaD
Sunitinib—MAP2K2—Signaling Pathways—HRAS—urinary bladder cancer	4.09e-07	3.08e-06	CbGpPWpGaD
Sunitinib—CYP3A5—Metabolism—PTEN—urinary bladder cancer	4.07e-07	3.07e-06	CbGpPWpGaD
Sunitinib—FYN—Signaling Pathways—TP53—urinary bladder cancer	4.02e-07	3.03e-06	CbGpPWpGaD
Sunitinib—MAP2K1—Signaling Pathways—TP53—urinary bladder cancer	4e-07	3.02e-06	CbGpPWpGaD
Sunitinib—PDGFRB—Signaling Pathways—HRAS—urinary bladder cancer	3.99e-07	3.01e-06	CbGpPWpGaD
Sunitinib—CYP3A4—Metabolism—TYMS—urinary bladder cancer	3.9e-07	2.94e-06	CbGpPWpGaD
Sunitinib—CYP3A5—Metabolism—EP300—urinary bladder cancer	3.88e-07	2.93e-06	CbGpPWpGaD
Sunitinib—CYP3A4—Metabolism—GSTM1—urinary bladder cancer	3.85e-07	2.91e-06	CbGpPWpGaD
Sunitinib—CYP3A4—Metabolism—NCOR1—urinary bladder cancer	3.85e-07	2.91e-06	CbGpPWpGaD
Sunitinib—FYN—Signaling Pathways—HRAS—urinary bladder cancer	3.85e-07	2.9e-06	CbGpPWpGaD
Sunitinib—MAP2K1—Signaling Pathways—HRAS—urinary bladder cancer	3.83e-07	2.89e-06	CbGpPWpGaD
Sunitinib—JAK2—Signaling Pathways—TP53—urinary bladder cancer	3.82e-07	2.88e-06	CbGpPWpGaD
Sunitinib—CYP3A4—Metabolism—GPX1—urinary bladder cancer	3.69e-07	2.78e-06	CbGpPWpGaD
Sunitinib—JAK2—Signaling Pathways—HRAS—urinary bladder cancer	3.66e-07	2.76e-06	CbGpPWpGaD
Sunitinib—CYP3A4—Metabolism—ERCC2—urinary bladder cancer	3.62e-07	2.73e-06	CbGpPWpGaD
Sunitinib—ABCB1—Metabolism—PTGS2—urinary bladder cancer	3.52e-07	2.66e-06	CbGpPWpGaD
Sunitinib—CYP3A4—Metabolism—MTHFR—urinary bladder cancer	3.4e-07	2.57e-06	CbGpPWpGaD
Sunitinib—ABCB1—Metabolism—PTEN—urinary bladder cancer	3.07e-07	2.32e-06	CbGpPWpGaD
Sunitinib—ABCB1—Metabolism—EP300—urinary bladder cancer	2.93e-07	2.21e-06	CbGpPWpGaD
Sunitinib—CYP3A4—Metabolism—PPARG—urinary bladder cancer	2.76e-07	2.08e-06	CbGpPWpGaD
Sunitinib—CYP3A4—Metabolism—CREBBP—urinary bladder cancer	2.65e-07	2e-06	CbGpPWpGaD
Sunitinib—CYP3A4—Metabolism—PTGS2—urinary bladder cancer	2.17e-07	1.64e-06	CbGpPWpGaD
Sunitinib—CYP3A4—Metabolism—PTEN—urinary bladder cancer	1.89e-07	1.43e-06	CbGpPWpGaD
Sunitinib—CYP3A4—Metabolism—EP300—urinary bladder cancer	1.81e-07	1.36e-06	CbGpPWpGaD
